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1. Introduction
1.1

Oxidative Stress and Cancer Progression.
Cancer progression has been viewed as an evolved adaptation of normal

cells to a sustained cancer stress microenvironment by succeeding matched
gene mutations and cellular non-genetic alterations.

Cellular adaptive

consequences result in multiple malignant phenotypes, including self-sufficiency
in growth signals, insensitivity to anti-growth signals, evading apoptosis, limitless
replicative potential, sustained angiogenesis and tissue invasion and metastasis,
which are known as six hallmarks of cancer.

1

In the past decade, another two

emerging hallmarks have been added to this list, known as reprogramming of
energy metabolism and evading immune destruction. 2
Oxidative stress is defined as an imbalance of the pro-oxidant antioxidant
ratio and is characterized as an increase in reactive species (RS). RS are the
essential components of cellular redox system and play multiple roles in human
physiology and pathology, including two main groups – ROS (derived from
oxygen, such as superoxide (O2-·), hydrogen peroxide (H2O2), hydroxyl radical
(·OH)) and RNS (containing nitrogen, such as nitric oxide (NO·) and peroxynitrite
(-ONOO)). 3 Oxidative stress has been implicated in cancer development through
modifying cellular structure, gene expression and enzyme function.

4,5

The

etiological study of cancer has indicated that oxidative DNA lesions are
correlated with the tumor related gene mutations.

6,7

However, some cancer

pathological studies also argued that the increase of oxidative DNA lesions, such
as 8-OH-G, is not sufficient to cause malignancy.

1

6,7

In non-malignant cells, the

elevated level of cellular oxidative DNA lesions may also cause apoptosis or
cytotoxicity. In addition, cellular DNA repair process plays an important role for
maintain genome stability through limiting the elevated oxidative DNA lesions. A
previous study indicated that RS could also impair cellular DNA repair machinery
and result in the accumulation of DNA mutations.

8

Besides the direct genetic

modification, studies have also demonstrated the crucial role of RS in mediating
the tumorigenic function of some non-genotoxic carcinogens.9 These findings
suggested that oxidative stress plays an important role in cancer signal
transduction.

Further, tumorigenesis studies have demonstrated that RS is

required to mediate downstream pathway activation of oncogenes and functional
inactivation of tumor suppressors.

10,11

Because persistent oxidative stress can

induce various cellular damages, RS also serves as a stress source to trigger cell
adaptation and select the malignant seeds leading to abnormal cell growth and
survival.

12

Besides regulating cell survival, RS functions as microenvironment

stimuli that reprograms cell energy or redox metabolism, and causes Warburg
effect or the enhanced content of the detoxification factor glutathione (GSH) in
malignant cells. 13
1.1.1 Reactive Species Induce Modification of Biological Molecules.
According to chemical electron status, RS are divided into two groups,
radical and non-radical species. Free radical RS refer to those with an unpaired
electron, which have high free energy and are very reactive. Superoxide (O2-·),
hydroxyl radical (·OH) and nitric oxide (NO·) are three main cellular radical RS.
RS that possess all-paired electrons are called non-radical RS and have a strong

2

oxidizing capacity. Hydrogen peroxide (H2O2) and peroxynitrite (-ONOO) are two
main non-radical RS.

Among these RS, O2-· and NO· are two main direct

byproducts of cell metabolism which are regulated by subsequent cellular redox
reactions.

14

In general, RS can induce damage, oxidation and nitration on cell

molecules.
The oxidative DNA lesions are the most common effects of RS. Besides
the direct modification on DNA (8-OH-G), RS also induce nucleotide base
oxidation and generate pre-mutagenic lesions, such as 8-OH-dGTP and 2-OHdATP.

15

These oxidized DNA precursors are incorporated into cell genome DNA

by DNA polymerase, and further cause cell mutagenesis. 16 This observation was
also supported by studies in which activation of MTH1 was shown to hydrolyze
and suppress the accumulation of oxidized nucleotides and decrease the rate of
tumor formation in aged mice.

17,18

In addition to direct genetic modification, RS

are also shown to be correlated with DNA methylation, an epigenetic code
suppressing gene expression. The increase of DNA methylation is commonly
coincident with increased pro-oxidants or down-regulation of antioxidants.

19-21

Furthermore, the impairment of cellular DNA repair system by RS plays a crucial
role in the development of genome instability. DNA strand break rejoining and
base excision repair are the main cellular repair machineries protecting DNA
against oxidative damage with the reductive environment being important for
these processes.
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Elevated cellular RS, such as H2O2, create a pro-oxidant

intracellular microenvironment, attenuate the cellular DNA repair activity, and
lead to the accumulation of un-repaired gene mutations. 22

3

Additionally, RS such as ·OH and NO·, also induce post-translational
modifications on protein products.

23,24

RS-induced reversible modifications,

such as disulfide bond formation, are largely involved in cell signaling
transduction; while RS-induced irreversible modifications, such as carbonylation,
are mainly viewed as the oxidative stress-induced protein damage or cellular
oxidative stress sensors.

24,25

There are several groups of amino acid residues

that have been reported mutated or modified by RS in tumor cells, including
sulfur-containing amino acids, carbonylation targeting amino acids and the
phosphorylation site residues of proteins.

26,27

Cysteine is a common RS-

sensitive sulfur-containing amino acid, which derives multiple oxidative stressgenerated products. Mild and moderate oxidative stress result in the reversible
cysteine modification, such as S-Nitrosylation, glutathionylation Cys-SH, intra- or
inter-disulphide bond formation Cys-S-S-Cys, mixed disulphide Cys-S-Sglutathione and sulfenic acid Cys-SOH. These types of modifications may alter
protein conformations and reversibly inhibit or activate enzymes, such as p53,
Ras and Akt. Excessive oxidative stress promotes irreversible oxidized products
which permanently change the protein activation, such as sulphinic acid CysSO2H and sulphonic acid Cys-SO3H. In addition, carbonylation is also a common
irreversible event caused by excessive oxidative stress and leads to damaging
alterations to protein functions. RS induce direct oxidative carbonyl formation of
lysine, arginine, proline and threonine. Lysine, cysteine and histidine can also
undergo carbonylation through interaction with the lipid and glycation oxidative
products.

In addition, methionine is another sulfur-containing amino acid,
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oxidized to methionine sulfoxide by RS. This reversible modification is important
for the regulation of calmodulin, which is an essential calcium regulatory protein.
28

Furthermore, tyrosine phosphorylation induced by RS is an important process

that regulates cellular kinase activity and functions in multiple-type tumors and
leukemia. Intra-disulfide bond formation in tyrosine kinase protein, such as cABL, interrupts the protein kinase activity through regulation of the stability of
tyrosine phosphorylation.

29

The nitration of tyrosine, a reversible modification

caused by RNS (nitrogen containing RS) prevents phosphorylation and
suppresses protein activation, as evidenced by studies of JNK and PKC.

28

Furthermore, the irreversible oxidative modification Tyr–Tyr crosslink Di-Tyr
induced by excessive oxidative stress blocks the phosphorylation-mediated
regulation at tyrosine.

30

Cellular lipids are highly diverse, interacting with proteins to form plasma
membranes mediating cellular signal transduction, and are also sensitive to
oxidative stress.

The most common RS-mediated lipid modification is lipid

peroxidation which leads to conformation alteration and oxidative degradation of
lipids.

31

During lipid peroxidation, lipids transfer electrons or lose allylic

hydrogens to RS generating fatty acid radicals, lipid peroxides or cycling
peroxides. This process mainly affects polyunsaturated fatty acids, which contain
multiple double bonds and act as the reactive hydrogen donors. The entire
process includes two main steps: initiation and propagation. Highly reactive RS,
such as ·OH and –ONOO, can react with lipids and produce unstable primary
fatty acid radicals.

After initiation, the primary fatty acid radicals react with

5

molecular oxygen and further generate unstable peroxyl-fatty acid radicals. The
peroxyl-fatty acid radicals may react with other fatty acids to form new fatty acid
radicals and lipid peroxides or just cyclic peroxides. This process is a continuous
cycle due to the new fatty acid radical formation which subsequently changes the
cellular lipid conformation. Cellular antioxidants, especially the phospholipid
hydroperoxide glutathione peroxidase, can scavenge lipid radicals and terminate
the lipid peroxidation chain reaction. The deficiency of such cellular antioxidants
results in an elevated lipid peroxidation or damage of cellular membrane
structures, and subsequently activates cellular stress-sensitive signaling
pathway.31
1.1.2 Reactive Species Function in Tumor Growth Signal Transduction.
Studies have identified that RS can function as signal transduction factors
that promote cell growth.

1

Cell mitogenic growth factors, such as PDGF and

TGFα, can promote mitosis through the activation of receptor kinase pathway,
notably PDGFR/Ras/MAPK pathway. This pathway has been demonstrated as a
redox sensitive pathway.

32

RS play a role in activated phosphorylation of

tyrosine kinase receptor and Ras through protein thiol modification, and further
stimulate the downstream MAPK pathway activation.

32

In addition, RS induce

the oxidative inactivation of a specific phosphatase, which inhibits this pathway
that promotes the dephosphorylation of the kinases.

32

Signal transduction

mediated by RS has also been reported in a study of tumor-related angiogenesis.
Angiogenesis, the process of the new blood vessel formation, plays an essential
role in tumor progression and metastasis. Tumor cell-secreted VEGF stimulates

6

the activation of endothelial cells and promotes angiogenesis.

During this

process, RS function in up-regulating the VEGF expression and mediate the
activated of VEGFR downstream pathway.

33

HIF-1 is the important transcription

factor to up-regulate VEGF expression in response to hypoxia.
heterodimer of HIF-1α and HIF-1β.

34

HIF-1 is a

HIF-1α is localized in the cytosol and

undergoes an oxygen-mediated degradation process. RS molecules, such as
O2-· and H2O2, block such degradation process and stabilize HIF-1α.

The

stabilized HIF-1α translocates to the nucleus to bind with HIF-1β to trigger the
transcription activity of HIF-1, and up-regulates VEGF expression as well. In
endothelial cells, VEGFR2 is the crucial VEGF receptor to mediate tumor cellstimulated tube formation.

RS, especially O2-· derived from cellular NADPH

oxidase, inhibit the tumor suppressor protein tyrosine phosphatases PTEN, and
stimulate the auto-phosphorylation-mediated activation of VEGFR2.

33

Besides

angiogenesis, RS is also involved in regulating integrins during metastasis.
Integrins are a group of cell surface transmembrane heterodimeric receptor
proteins, consisting of two non-covalently bound glycoprotein α and β. RS
promote integrin expression and further stimulate the communication between
tumor cells and extracellular matrix.35 The ligand binding affinity of integrins is
regulated by the disulfide formation between α and β glycoproteins, which is a
redox-sensitive process and depends on the levels of RS.

35

In addition, a late

stage of tumorigenesis is linked to extra-cellular matrix degradation, which is an
essential process for endothelial cells migration into the tumor tissue. Matrix
metalloproteinase (MMP) cooperates with integrins regulating cell invasion and
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metastasis.

5

MMPs are secreted from tumor cells and phagocytes (especially

macrophages).

36

RS and RS-sensitive growth factors are also involved in

regulating MMP expression. A study has shown that RS promote cellular MMP9
expression. Also, VEGF can up-regulate MMP1 and MMP2.

37,38

Besides the function in promoting cell growth, RS also function as a stress
source to promote cellular redox-sensitive survival machinery activation, such as
activating cell survival transcription factors, stimulating kinase pathways and
altering cellular metabolism.

28

Moderate levels of RS promote cell survival

through activation of transcription factors, such as NFκB, Nrf2 and HIF-1, as well
as kinase pathways, such as PI3K/Akt pathway.

28

NFκB mainly responds to

mitochondria derived RS, and up-regulates anti-apoptotic factors and survival
antioxidants, such as IAPs and SOD2.

28

Nrf2 mainly responds to the ER stress

and exogenous carcinogens, and promotes the expression of the acute stressinduced antioxidants and cellular detoxification factors, such as HO-1 and
glutathione (GSH) system factors.

28

HIF-1 mainly responds to the cellular

oxygen status, such as hypoxia, and stimulates the expression of angiogenesis
factors and energy-generating enzymes, such as VEGF and glycolysis pathway
enzymes.

28

Besides the above transcription factors, PI3K/Akt kinase pathway is

another crucial survival pathway involved in the cellular oxidative stress
response.

The survival function of PI3K/Akt pathway is mainly through up-

regulation of BCL-2 family anti-apoptotic factors, and inactive phosphorylation of
cellular pro-apoptotic factors or cell death signal mediators, such as BAD and
ASK1.

28

8

1.1.3 Reactive Species Disrupt Cell Cycle and Evades Cell Death.
In normal cells, multiple anti-growth signals maintain the cellular quiescent
status and regulate the homeostasis process that responds to the external or
intrinsic stress stimuli.

Tumorigenic stress may also force the benign cells into

cell cycle arrest or apoptosis. Malignant cells are believed to derive from the premalignant ones which successfully disrupt the normal cell cycle regulation and
escape from the stress-induced cell death.

1

RS are linked to this process and

serve as the stress source to promote malignancy transformation.
At the molecular level, pRb and p53 play important roles in regulating cell
cycle and function as tumor suppressors. Disruption of pRb or p53 is a key step
for tumor progression. Mammalian pRb and its relatives are the mediators of the
multiple cell arrest signals. Hyper-phosphorylation of pRb blocks cell cycle by
inhibiting the E2F transcription factors which control the expression of genes
involved in the normal cell cycle, especially from G1 to S stage.

39

The pRb

pathway cooperates with mitogenic signaling pathways to promote intracellular
RS generation. The increased RS activate PKCδ, which promotes the further
elevation of RS, and forms a RS-PKCδ feedback loop.

40

This RS-PKCδ loop is

not only involved in inhibition of cell proliferation but also in induction of cell
survival.

In addition, a previous in vitro study has suggested that pRb is

regulated by protein oxidation through oxidation of the specific methionine to
methionine sulfoxide.

41

This modification alters the serine phosphorylation of

pRb induced by kinases and disrupts the regulating function of pRb in cell cycle.
Similar to pRb, p53, another crucial factor that regulates cell proliferation, is also

9

regulated by RS, but in a more complicated process.

Responding to the

different levels of cellular oxdative stress, p53 promotes various biological
consequences, such as DNA repair, senescence and apoptosis.

5

The

expression of several crucial antioxidants is regulated by p53 at transcriptional
level, including GPX1, catalase and SOD2.

42

Additionally, p53 is also involved

in the regulation of cellular RS generation machineries, such as mitochondrial
respiratory chain. Conversely, function of p53 is also regulated by RS-mediated
protein modification. Protein phosphorylation induces controversy effects on p53
depending on the RS level.43 There are ten cysteine residues localized in p53
DNA binding region. RS could alter the p53 conformation by modifying these
cysteine residues. Such structure alterations cause the similar effects of p53
mutations, and attenuate the p53 DNA binding activity. One study has shown the
potential malignant biological consequences induced by p53 cycteine residue
oxidations.

Using an in vivo mouse model, researchers have observed that

interruption of redox-directed regulation of Cys173, 235 or 239 of p53 caused
complete loss of p53 tumor suppressor function as well as gained oncogenic
function.

44

This study showed the potential malignant biological consequences

induced by p53 cycteine residue oxidations.
Taken together, the cellular oxidative stress plays important roles in
cancer progression through induction of genome instability, interruption of cell
growth and promotion of cell survival. RS not only cause DNA mutations that
activate proto-oncogene or inhibit tumor suppressor, but also mediates malignant
signal transduction through various biological modifications (Figure 1).

10

Figure 1.

Biological functions of oncogene-induced ROS. The direct effects
from ROS and the relative biological consequences in malignant
cells are listed.
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Kinase activation
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regulation (inhibition)

Oxidation of Cys switch
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active/inactive

Active redox sensitive
transcription factors

Altered gene expression
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1.2

BCR-ABL Positive CML and Oxidative Stress.
Chronic myeloid leukemia (CML) causes abnormal growth and survival of

myeloid precursor cells in the bone marrow and blood.

CML represents

approximately 15-20% of all adult leukemia, and often occurs during or after
middle-age. CML is grouped into chronic, accelerated and blast crisis phases.
The chromosome 9/22 translocation (Philadelphia chromosome, Ph) has been
identified in about 95% CML cases.

Bcr-Abl fusion gene as the result of Ph

chromosome encodes a tyrosine kinase oncoprotein, which is constitutively
active and functions distinctly from the endogenous c-ABL. (Figure 2)

45-47

The

association between CML malignancy progression and BCR-ABL activation has
been demonstrated in vitro and in vivo.

48-50

There are several variants of BCR-

ABL oncoprotein, including 230 kD, 210 kD and 190 kD isoforms. The 210 kD
BCR-ABL (b2a2 or b3a2) is well studied and is linked with the development of
CML through suppression of normal hematopoiesis and promotion of abnormal
cell survival in hematopoietic progenitor cells. 51,52

13

Figure 2.

The formation of Ph Chromosome and BCR-ABL fusion gene.
BCR locates on chromosome 22. ABL locates on chromosome 9.
Chromosome 9/22 translocation generates Ph chromosome and
BCR-ABL fusion gene.

14
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1.2.1 BCR-ABL Induces Cellular ROS Elevation.
The elevation of cellular oxidants plays an important role in malignancy
initiation and progression by creating a favorable environment for cancer and
leukemia cell.

53-57

Superoxide (O2-·) and hydrogen peroxide (H2O2) are the two

most abundant stable forms of intracellular ROS.

Mitochondria and cellular

membrane bound NADPH oxidases (NOXs) are key sites for ROS generation in
leukemia cells. The accumulation of the intracellular O2-· and H2O2 is mainly
regulated by superoxide dismutases (SODs) and glutathione peroxidases
(GPXs).

14

The oxidative environment results in a self-perpetuating process and

induces tumorigenesis-associated gene mutations by DNA damage. In addition,
oxidative

stress

also

induces

protein

modifications

and

activates

the

carcinogenesis-related transcription factors or kinases.
The increased oxidative DNA damage and the elevated intracellular ROS
production have been observed in BCR-ABL transformed cells, which can be
abrogated by the treatment of BCR-ABL kinase inhibitor or ROS scavenging
agents.

58-60

The consistent genetic and redox alterations have been found in

human CML primary cells compared with normal bone marrow cells from healthy
donors.

58,59,61

Furthermore, the mechanistic study of BCR-ABL-induced ROS

elevation has demonstrated that BCR-ABL-induced ROS increase is associated
with phosphorylation at Tyr-177 residue of BCR-ABL, activation of PI3K pathway,
up-regulation of cellular glucose metabolism and
respiratory chain activity. 60,62,63
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elevation of mitochondrial

1.2.2 ROS and BCR-ABL Activation.
The kinase activity of BCR-ABL is related with its tyrosine residue
phosphorylation status, which is negatively regulated by protein tyrosine
phosphotases (PTPase) through dephosphorylation.

Previous studies have

demonstrated that H2O2 induces the same effective inhibition of PTPase as
PTPase inhibitor pervanadate in non-malignancy human megakaryocytic cell
MO7e. The inhibition of PTPase by H2O2 can enhance phosphorylation and
tyrosine kinase activity of proto-oncogene c-ABL.

62

These results have indicated

that ROS may contribute to the constitutively tyrosine kinase phosphorylation of
BCR-ABL by suppressing PTPase-mediated protein dephosphorylation. Besides
regulating PTPase activity, ROS has been shown to stabilize tyrosine
phosphorylation of BCR-ABL through generation of protein intra-disulfide bond
formation.

64

In addition, clinic and laboratory studies have identified that the

elevated cellular ROS contributes to the generation of tyrosine kinase inhibitorresistant mutants by promoting oxidative DNA damage of native BCR-ABL in
CML cells. 59
1.2.3 BCL-XL Mediates Cell Death Resistance in BCR-ABL Cells.
BCR-ABL functions in evading apoptosis and promoting abnormal survival
in CML cells.

65

B-cell lymphoma-extra large (BCL-XL) is a crucial downstream

survival factor of BCR-ABL.

66,67

BCL-XL enhances cell survival through

suppressing the activation of pro-apoptotic factors.

68

In addition, BCL-XL has

been found to attenuate growth factor withdrawal or CD95 activation-induced cell
death by preventing the depletion of cellular GSH.
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69,70

High intracellular GSH

content is the crucial metabolic cofactor for the development of drug-resistance
and abnormal cell survival.

71-73

One recent study has identified that over-

expression of BCL-XL may cause the dramatic increase of cellular GSH through
activation of pentose phosphate pathway.

74

A previous study has demonstrated

that BCR-ABL promotes BCL-2 independent anti-apoptotic function through upregulating BCL-XL.

75

Inhibition of BCR-ABL by ABL kinase inhibitor CGP 57148

(Imatinib) induces severe cell death along with the down-regulation of BCL-XL in
CML cell line K562. Over-expression of BCL-XL in parental K562 cells prevents
CGP 57148-induced cell death.

76

BCR-ABL-induced BCL-XL up-regulation is

mainly mediated by signal transducer and activator of transcription 5 (STAT5).

77

The cytokine-independent and kinase-dependent constitutive activation of STAT5
has been demonstrated in CML cells.

78

Previous studies have identified that

both SH2 domain and SH3 domain proline-rich binding sites of BCR-ABL are
required for the activation of STAT5.79 Additionally, hematopoietic cell kinase
(Hck) interacts with BCR-ABL SH2 and SH3 domains as a downstream activation
kinase of BCR-ABL. The activation of Hck leads to the phosphorylation of
STAT5B on Tyr699 residue and stimulates the activation of STAT5.

80

Intriguingly, two recent studies have indicated that both IL-3R/JAK2 dependent
and independent regulation play important roles in up-regulating BCL-XL in BCRABL-expressing cells.
mediating

81

up-regulation

The elevation of cellular ROS may also be involved in
of

BCR-ABL,

because

previous

studies

have

demonstrated that the increase of cellular ROS can mediate the activation of
STATs in non-BCR-ABL cells, including STAT1, STAT3 and STAT5.
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82,83

Additionally, BCL-XL repressor, interferon consensus sequence binding protein
(ICSBP) is also dramatically down-regulated in chronic stage CML patients.

84,85

Taken together, it is suggested that BCL-XL is a specific BCR-ABL downstream
survival factor activated through multiple modes of regulation.
1.2.4 Glutathione Redox Buffer System.
Glutathione (GSH) is a ubiquitous small thiol peptide at mM range
concentrations, and functions as the essential intracellular redox buffer factor in
mammalian cells.

73

Under normal physiological condition, cellular ROS

scavenging function mainly depends on GSH metabolism. GSH functions as the
substrate for the reduction of H2O2 to H2O by GPXs. GSH oxidized product
GSSG is recycled back to the reduced form of GSH by glutathione reductase
(GR).

86

GPX1 is the most abundant intracellular GPX enzyme and plays a key

role to scavenge H2O2.

87

Therefore, both intracellular GSH content and GPX1

activity are important for maintaining proper cell redox balance. Cellular GSH
content is associated with GSH synthesis, transport and distribution. Two key
enzymes, γ-Glutamyl-cysteine synthetase (GCLC) and glutathione synthase
(GSS) catalyze GSH synthesis using glutamate, cysteine and glycine as
substrates.

88

The intracellular and extracellular GSH transport and distribution

are regulated by Gluathione-S-transferases (GSTs) and membrane GSH efflux
pumps. 89
1.2.5 Clinical Application of BCR-ABL Targeting Inhibitors.
In the past few years, BCR-ABL targeting inhibitors have been developed
for the chemotherapy of CML.

90

Imatinib mesylate (Gleevec) has shown high

19

clinical response rate and represents the first generation of BCR-ABL tyrosine
kinase inhibition reagents. Due to its good selectivity, Imatinib has become the
front-line reagent for CML.

91,92

This merit of Imatinib has been demonstrated by

both a long term randomized clinical study and the successful clinical trial of
higher dose Imatinib in CML therapy.

93-95

However, only about 65-75% of early

stage CML patients respond to Imatinib. Moreover, more advanced stage of
CML are resistant to Imatinib. In addition, a set of BCR-ABL mutants have been
identified to cause Imatinib-refractory CML in patients. These mutants result in
the three-dimensional structure alteration at the kinase activation site, and induce
constitutive kinase activity due to the decrease in Imatinib affinity.

96-99

In order to

overcome Imatinib-resistance, the second generation BCR-ABL tyrosine kinase
inhibitors have been developed. Dasatinib (BMS0354825), one of these second
generation inhibitors, has been approved for the treatment of CML by the FDA.
Clinical trials have demonstrated that Dasatinib effectively eliminates various
Imatinib-resistant mutants except the one harboring BCR-ABL-T315I mutation.
100-102

The limitations of BCR-ABL inhibitor reagents have inspired the

development of alternative therapeutic strategies dependent on the further
understanding of drug resistance in CML. 103,104
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2. Hypothesis and Specific Aims
The major goal of this study is to understand the role of BCR-ABL in
inducing persistent intracellular oxidative stress in CML. Oxidative stress occurs
with an overabundance of ROS, and results in cell differentiation or apoptosis
under normal physiological conditions. Previous studies have demonstrated that
BCR-ABL promotes malignancy development along with the increases of cellular
and mitochondrial ROS generation.

However, the essential survival factors

protecting CML cells against oxidative stress are still unclear. The increase of
ROS generally triggers the antioxidant response which protects against
apoptosis through activation of intracellular redox enzymes. But, are there any
unique cell survival machineries responsive to oxidative stress in malignant
cells? This is a question worthy of further investigation. Previous studies have
found that several molecular factors functioning in antioxidant enzyme
expression are dysfunctional in BCR-ABL cells, such as FOXO3, ATM/ATR and
P53.

105-107

Consistently, some antioxidant enzymes specifically responsive to

intracellular H2O2 accumulation are decreased in some BCR-ABL positive
patients or cultured human CML cells, such as GPX1 and catalase.

92,108

It is

worth noting that some transcription factors responding to oxidative stress are
up-regulated or activated in BCR-ABL cells, such as STAT5 and NF-ĸB.

77,109

Furthermore, their downstream anti-apoptotic factors are over-expressed in BCRABL cells, such as BCL-XL and BCL2.

75,110

These findings suggest that BCR-

ABL may render cells to be more dependent on anti-apoptotic factors rather than
antioxidant enzymes in tolerating intra- or extra-cellular oxidative stress. Taken
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together, I hypothesize that BCR-ABL induces mitochondrial oxidative
stress, while protecting against oxidative stress-induced CML cell
apoptosis through up-regulation of BCL-2 family survival factors.
To address the above hypothesis, I will investigate the following specific
aims in this study:
Aim 1: Identifying the function of glucose metabolism in BCR-ABLinduced mitochondrial oxidative stress.

Previous studies have indicated that

glucose metabolism is important for mitochondrial ROS increase in cells stably
transfected with BCR-ABL.

60,62,63

Whether such biological alterations are either

initial changes induced by BCR-ABL or late adaptations to malignant signals is
still unknown. Therefore, the BCR-ABL inducible model will be used to evaluate
the correlation between glucose metabolism and mitochondrial ROS level.
Aim 2: Investigating the role of BCL-2 and BCL-XL in protecting CML cell
against oxidative stress-induced apoptosis. Up-regulation of BCL-2 and BCL-XL
in leukemia has been identified by numerous studies.

75,110

BCL-XL is the direct

downstream survival factor of BCR-ABL through activation of STAT5. BCL-2
functions in malignant development, and mediates BCR-ABL-independent
Imatinib-resistance in some CML patients.

111

In addition, the heterogeneous

BCL-XL and BCL-2 has been observed in CML cells. The goal of this specific
aim is to identify the dominant survival factors responsive to oxidative stress in
CML. To achieve this goal, BCR-ABL inducible cells, CML cells with differentially
expressing levels of BCL-XL and BCL2, genetically modified BCL-XL or BCL-2
expressing cells and BCR-ABL stable transformed cells will be used. The initial
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survival factor responsive to BCR-ABL induction will be evaluated.

The

sensitivity of oxidative stress-induced apoptosis and the biological alterations of
mitochondria will be tested in the cells with differential level of BCL-XL and BCL2 expression.
Aim 3: Testing the cell killing effects of redox modulating agents in CML.
BCR-ABL-induced ROS elevation plays an important role in malignancy
development.

On the other hand, such enhanced ROS accumulation might

serve as a biochemical basis to preferentially promote cell apoptosis via further
oxidative stress induction. BCR-ABL contains multiple redox-sensitive cysteine
residues which could be oxidized by ROS and cause protein instability. Previous
studies have suggested that modulation of cellular antioxidant GSH content by Nacetylcysteine (NAC, an antioxidant) or BSO (an inhibitor of glutathione
synthesis) affects BCR-ABL stability.

112,113

Based on the previous findings, I will

use a redox modulating agent, β-phenylethyl isothiocyanates (PEITC, a natural
compound found in edible cruciferous vegetables) to target the cellular
glutathione (GSH) system and test the cell viability of CML cells.

In addition, I

will also test redox modulation-induced cell killing effects in cells harboring T315IBCR-ABL (the most drug-resistant BCR-ABL mutant observed in clinic), T315IBCR-ABL transformed cells and T315I-BCR-ABL positive patient samples.
Furthermore, the effective combination of redox modulating agents and other
drugs will be also investigated.

CML cells exhibit substantial phenotypic

heterogeneity. Certain sub-populations of cells carrying a secondary mutation,
such as BCL-2, often escape from primary treatment of Imatinib and enhance
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disease recurrence risk. Even under the condition that Imatinib is efficient to
inhibit the activation of BCR-ABL, the diseased cells may still survive but become
more sensitive to extreme stress. Using a redox modulating agent PEITC as a
combination agent may promote massive cell death in such cells. To test this
point, I have established a cell model with fluorescence-linked heterogeneous
BCL-XL and BCL-2 expression in CML cells. Imatinib or oxidative stress-induced
cell death will be investigated in the cells with different BCL-XL and BCL-2
genetic background.
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3. Materials and Methods
3.1

Chemicals and Reagents.
Doxycycline, 30% H2O2, β-phenylethyl isothiocyanate (PEITC, C9H9NS),

N-acetyl cysteine (NAC), and bovine catalase were purchased from SigmaAldrich (St. Louis, MO).

Imatinib mesylate (Gleevec) and ABT737 were

purchased from Chemie Tek (Indianapolis, IN).

‘Active caspas-3, caspase

inhibitors Z-VAD-FMK and Z-DEVD-FMK were obtained from BD Biosciences
(San Jose, CA).

The proteasome inhibitor MG132 was acquired from EMD

biosciences (Calbiochem, San Diego, CA). Drugs were dissolved in DMSO and
further diluted with culture medium before use. The final DMSO concentrations
in the cell culture medium were less than 0.1% (v/v).

Bovine catalase was

freshly dissolved in culture media and sterilized by passing through 0.2 µm sterile
syringe filter (Corning, NY) before use.’114
3.2

Plasmid Transfection.
Human HA-Bcl-XL plasmid was a gift from Dr. Paul Chiao and Dr.

Xiangwei Wu (MD Anderson Cancer Center, The University of Texas). Human
GFP-Bcl2 plasmid was obtained from Addgene (Cambridge, MA). Tet-on Human
Bcl-XL shRNA plasmid was purchased from Thermo Scientific-Open Biosystems
(Huntsville, AL).

All the transfection reagents were purchased from Life

Technologies-Invitrogen (Carlsbad, CA). Cells were starved in serum free media
for 8-12 hours, and then seeded at 1E6 cells/ml in six-well plates. Plasmid DNA
2 – 4 µg was diluted by 500 µl Opti-MEM (Invitrogen), and transfected into cells
using lipofectamine 2K (Invitrogen). Transfected cells were cultured in serum
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free media for another 12 – 24 hours, and then diluted into 2E5cells/ml in culture
media with 10% serum. 2 µg G418 (Cellgro, Manassas, VA) was used in the
selection for HA-Bcl-XL and GFP-Bcl2 transfected cells. 4 µg Puromycin was
used in selection for Tet-on Human Bcl-XL shRNA transfected cells. After one
month of selection, the enriched HA-Bcl-XL or GFP-Bcl2 transfected cell pools
were tested for the presence of transgene by Western blotting. The enriched
Tet-on Human Bcl-XL shRNA transfected cell pool was maintained in tetracycline
free media and decrease of BCL-XL in the presence or absence of doxycycline
0.5 – 1.0 µg/ml was tested by Western blotting.
3.3

Cell Lines and Cell Culture.
‘All human and murine BCR-ABL positive cells were maintained in RPMI

1640 medium with 10% fetal bovine serum (FBS) at 37°C in an atmosphere of
5% CO2 balanced humidified air. K562 cell line expressing the 210 kD BCR-ABL
protein was derived from a female myeloid CML patient in blast crisis.

115

KBM5

cell line expressing the 210 kD BCR-ABL protein was derived from a female
myeloid CML patient in blast crisis.

116,117

KBM5-T315I was derived from KBM5

by exposing to increasing concentrations of Imatinib leading to the selection of
surviving clones harboring T315I mutation.

118

KBM5-T315I cells were routinely

maintained in culture medium containing 1 µM Imatinib. In studies where KBM5T315I cells were compared with the parental KBM5 cells, Imatinib was washed
off and KBM5-T315I cells were cultured in drug free medium for several days
before the experiments. All the murine cells are gifts from Dr. Ralph Arlinghaus
(MD Anderson Cancer Center, The University of Texas). TonB210 cell line was
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derived from the murine BaF3 cells by transfection using Tet-on BCR-ABL.
TonB210 cells were maintained with IL3 at 1.0 – 4.0 ng/ml. The induction of
BCR-ABL was through addition of 0.5 – 1.0 µg/ml doxycycline into culture media.
32D-p210 cells were derived from the murine 32D cells by transfection using
BCR-ABL. Parental 32D cells were maintained with 1.0 – 4.0 ng/ml IL3. BaF3Bcr-Abl cells and BaF3-Bcr-Abl/T315I cells were derived from the murine BaF3
cells by transfection using BCR-ABL or T315I-mutated BCR-ABL.
3.4

119-121 114

‘

Isolation of Primary CML Cells.
‘Normal lymphocytes and primary CML cells were isolated from fresh

peripheral blood samples from health donors and CML patients, respectively,
after obtaining informed consent in accordance with a research protocol
approved by M. D. Anderson Cancer Center institutional review board (IRB).
Patients CML1 and CML2 were at blast crisis stage. Patient CML2 was identified
to carry BCR-ABL-T315I mutant.

Cells were isolated using gradient

centrifugation with Fico/Lite lymphoH (d=1.077, Atlanta Biologicals, Atlanta, GA).
After isolation, cells were washed by phosphate-buffered saline (PBS) and
suspended in fresh culture medium. All drug treatments started after the cells
were pre-cultured for 24 hours. The peripheral blood specimens were obtained
from CML patients after proper informed consent under a research protocol
approved by IRB of the University of Texas MD Anderson Cancer Center.’114
3.5

Measurement of Cellular ROS.
‘Cellular ROS contents were measured by incubating the control and

experimental cells with 1.0 - 2.5 µM of CM-H2DCF-DA (Life technologies-
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Invitrogen, Carlsbad, CA) for 60 minutes as the chemical probe for ROS.

CM-

H2DCF-DA is cell membrane permeable, and once insider cells, reacts with H2O2
and other ROS species to generate green fluorescence. The intensity of green
fluorescence, reflecting cellular ROS contents, was measured by flow cytometric
analysis. ‘114
3.6

Measurement of Mitochondrial ROS.
Mitochondrial ROS contents were measured by incubating the control and

experimental cells with 1.0 - 2.0 µM of MitoSOX Red (Life technologiesInvitrogen, Carlsbad, CA) for 60 minutes as the chemical probe for mitochondrial
ROS.

MitoSOX Red is cell membrane permeable, and accumulates in the

mitochondria and mainly reacts with superoxide to generate red fluorescence.
The intensity of red fluorescence, reflecting mitochondrial ROS contents, was
measured by flow cytometry.
3.7

Measurement of Cell Lactate Release.
Cell lactate production during growth was detected by the Accutrend

Lactate analyzing system purchased from Roche (Mannheim, DE). Differentially
treated cells were incubated in fresh media for 48 hours. Each aliquot of the
cultured media was collected at a volume of 30 µl to detect lactate concentration
in a range between 0.8 – 22 mM according to manufacturer’s instruction.
3.8

Oxygen Consumption in Whole Cells.
Oxygen consumption in cells was measured by a Clark type oxygen

electrode system purchased from Hansatech Instruments (Norfolk, UK). Cells
were incubated with different experimental conditions, and then harvested by
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centrifugation. The samples were resuspended in air saturated 37°C media (O2
21%) and immediately added into the oxygen chamber.

The oxygen

consumption rate was measured in the sealed off chamber for 15 minutes.
Oxygen consumption curves were generated for each experimental condition.
3.9

Measurement of Mitochondrial Membrane Potential.
Mitochondrial membrane potential was assessed by the cationic voltage-

sensitive lipophilic dye Rhodamine 123 (Life technologies-Invitrogen, Carlsbad,
CA). Cells were incubated with different experimental conditions and labeled
with 200 nM Rhodamine 123 for 30 minutes. The fluorescence of Rhodamine
123 in the washed and resuspended samples was measured in channel FL-2 by
flow cytometry. The dramatic drop of florescence is indicative of mitochondrial
membrane collapse.
3.10

Detection of GFP-BCL2 Mitochondrial Localization.
MitoTracker Red (CMXRos, Life technologies-Invitrogen, Carlsbad, CA), a

red fluorescent dye to stain mitochondria in live cells, was used to visualize
mitochondria.

Mitotracker Red was directly added into cell suspensions at 200

nM for 60 minutes. Total 0.5E5 cells of each sample were collected for cytospin.
The slides and filters were placed into appropriate slots in the cytospin. Cells
were loaded into chamber and collected onto slide by spin down at 1000 RPM 10
minutes (Shandon Cytospin 2). The samples on slides were washed with cold
PBS twice and fixed with 4% paraformaldehyde for 20 minutes. Samples were
then coated with Mounting Medium with DAPI purchased from UltraCruz (Santa
Cruz, CA), and further analyzed by confocal microscope.
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3.11

Isolation of Mitochondria.
Cell pellets were washed with cold PBS, and then resuspended in RSB

buffer (10 mM NaCl, 1.5 mM CaCl2, 10 mM Tris-HCl, pH 7.5) to allow cells TO
swell for 10 minutes. The pellets were homogenized with a tight-fit glass tissue
homogenizer for 10 strokes, and the mixed with 2.5 X MS buffer (525 mM
mannitol, 175 mM sucrose, 12.5 mM Tris-HCl, pH 7.5, 12.5 mM EDTA) to the
final 1 X MS buffer concentration. Nuclei and unbroken cells were removed from
homogenates by centrifugation at 1300 g for 5 minutes twice. The supernatants
were transferred to fresh tubes and centrifuged at 17,000 g for 20 minutes to
pellet mitochondria fragments. The mitochondria pellets were further washed
with 1 X MS buffer three times, and then resuspended in SDS lysis buffer for
Western blotting analysis.
3.12

Measurement of Cellular Glutathione.
Two different methods were used to evaluate cellular glutathione. ‘In one

way, total cellular glutathione contents were measured by using a DTNB-enzyme
cycling glutathione assay kit (Cayman Chemical, Ann Arbor, MI). Cell extracts
were prepared from the control or drug-treated cells by sonication and
deproteinization. The glutathione and DTNB reaction product, yellow colored
TNB, was detected by 96-well plate reader at absorbance A414 nm. The cellular
glutathione contents were calculated using the standard curve generated in the
experiments with parallel standard glutathione samples, and data from each
individual experiment were normalized to control (100%).’114 In the other way,
relative cellular glutathione levels were measured by incubating the control and
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experimental cells with 200 - 400 nM of CMFDA (Life technologies-Invitrogen,
Carlsbad, CA) for 60 minutes as the chemical probe for cellular thiols. CMFDA is
cell membrane permeable, and reacts with thiols to generate green fluorescence.
The intensity of green fluorescence, mainly reflecting free glutathione contents
(98%), was measured by flow cytometry.
3.13

Quantitative Real-Time PCR Analysis for GPX1 Expression.
32D and 32D-p210 cell pellets were collected at the exponential growth

stage.

Total RNA of each sample was isolated using TRIzol Reagents

purchased from Life technologies-Invitrogen (Carlsbad, CA).

The first strand

cDNA was generated from 1µg total RNA by reverse transcription using
SuperScript VILO cDNA Synthesis Kit purchased from Life technologiesInvitrogen (Carlsbad, CA). The mRNA expression file of Gpx1 was assessed by
real-time PCR analysis using SYBR Green PCR Kit purchased from Life
technologies-Applied Biosystems (Carlsbad, CA). The primers used in this assay
are listed as following: Murine GPX1 forward 5’-CATTGCCTGGAACTTTGAGA3’, reverse 5’-CGATGTCGATGGTACGAAAG-3’; Murine ACTB forward 5’CTCTTCCAGCCTTCCTTCCT-3’, reverse 5’-TGCTAGGGCTGTGATCTCCT-3’.
3.14

Immunoblot Analysis.
‘Protein lysates were prepared from the control and drug-treated cells,

separated by electrophoresis on 8% to 15% SDS-PAGE, and transferred to
nitrocellulose membranes. The molecules of interest were detected using specific
antibodies as described previously. Primary rabbit polyclonal antibodies against
full length and cleaved BCR-ABL, caspase-3, BCL-2, BCL-XL, GPX-1, MCL-1,
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BAX, HSP60, HA, phspho-c-ABL Tyr245 and phospho-FOXO3a Thr32 were
obtained from Cell Signaling Technology (Boston, MA). Primary mouse
monoclonal antibody against poly (ADP-ribose) polymerase (PARP) was
purchased from BD Transduction Laboratories (San Diego, CA). Mitochondrial
respiratory chain subunit antibodies were from MitoProfile Total OXPHOS
Human WB Antibody Cocktail purchased from MitoSciences (Abcam, Eugene,
OR). Actin was probed as a loading control.’114
3.15

Cytotoxicity Assays.
Three different methods were used to evaluate the cytotoxic effect of

drugs under various experimental conditions. ‘Cell viability was determined by 3(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay

122

.

Cells were treated with various concentrations of drugs in 96-well plates for 72
hours, and MTT reagent was added and incubated during the last 4 hours of the
drug treatment.

After washing off the culture medium, the cell pellets were

dissolved in 200 µl DMSO and OD 570nm was quantified using a 96-well plate
reader. Drug sensitivity was compared using the cell survival curves and the IC50
values, defined as the drug concentration that induced 50% loss of cell
viability.’114 Cell death was also determined by flow cytometric analysis after the
cells were stained with propidium iodide (PI) from BD Biosciences Pharmingen
(San Diego, CA). After cells were incubated with various experimental conditions
as indicated in the figure legends, the samples were stained with PI over night
and analyzed by flow cytometry. The red fluorescence generated by intracellular
PI is indicative of cell DNA content. The dead cells, presenting a dramatic loss of
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DNA, are named as sub-G1 population. The percentage of sub-G1 population in
the whole sample represents the status of cell death. Additionally, cell apoptosis
was determined by flow cytometric analysis after the cells were double-stained
with Annexin-V-FITC and PI, using an assay kit from BD Biosciences
Pharmingen (San Diego, CA).

After cells were incubated with various

experimental conditions as indicated in the figure legends, the samples were
stained with Annexin-V/PI.

The Annexin-V-FITC only positive cells are pre-

apoptosis cells. The Annexin-V-FITC and PI double positive cells are apoptosis
cells. The Annexin-V-FITC and PI double negative cells are viable.
3.16

Statistical Analysis.
The flow cytometry results were analyzed by BD FACSCalibur equipped

with Becton Dickson CellQuest Pro software (San Jose, CA) and FlowJo
(Ashland OR). The comparison between the control and experimental samples
were tested for statistical significance by the two-tailed Student’s t-test.
Significance was determined at p<0.05 and the 95% confidence interval. Data
analysis was performed with PRISM 5.0 (GraphPad, San Diego, CA)
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4. Results
4.1

BCR-ABL

Promotes

Mitochondrial

Oxidative

Stress

through

Enhancement of Glucose Metabolism.
4.1.1 Over-expression of BCR-ABL is Correlated with Cellular ROS Increase.
The murine BCR-ABL inducible cell line TonB210 was used to evaluate
the level of cellular ROS by probing with DCF-DA.

BCR-ABL expression is

induced by doxycycline ranging between 0.5 and 1.0 µg/ml. The BCR-ABL noninduced cells served as control and maintained in tetracycline free media with
IL3.

I further detected BCR-ABL expression and cellular ROS level at the

different time points during BCR-ABL induction.

BCR-ABL was detected by

Western blotting using anti-c-ABL antibody. The total cellular ROS was indicated
by the amount of green fluorescence derived from DCF-DA probe.

BCR-ABL

showed the time-dependent increase during induction at 12, 24 and 36 hour
points (Figure 3A). The consistent time-dependent increase of total ROS was
also observed in the samples with the increase of BCR-ABL expression (Figure
3B). Based on the above experimental results, this indicates that increase of
ROS is correlated with BCR-ABL over-expression.
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Figure 3.

Over-expression of BCR-ABL is correlated with cellular ROS
increase in TonB210 cells. (A) BCR-ABL was induced by 0.5 µg/ml
doxycycline in TonB210 cells. (B) Intracellular ROS was detected
by flow cytometry using DCF-DA probe in BCR-ABL overexpressing cells.
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4.1.2 Activation of BCR-ABL Causes the Enhancement of Glucose Metabolism.
TonB210 cells were cultured with or without doxycycline for 48 hours. The
doxycycline treated cells were either incubated with 5µM Imatinib or not.

Cells

were cultured with IL3 in order to prevent cell death in parental cells or Imatinib
treated BCR-ABL over-expressing cells. The amount of glycolysis end product
lactate released from the differentially treated TonB210 cells has been
measured.

BCR-ABL over-expressing cells showed a significant increase of

lactate products (Figure 4, Upper).

Furthermore, Imatinib significantly

suppressed the enhancement of lactate in BCR-ABL over-expressing cells
(Figure 4, Upper) along with the inhibition of BCR-ABL tyrosine kinase activation
(Figure 4, Lower). These results suggested that BCR-ABL onco-protein activity
is required for the enhancement of cellular glucose metabolism. In addition, no
dramatic changes of cell oxygen consumption were observed in BCR-ABL overexpressing cells (Figure 5). This result excludes mitochondria inhibition as the
cause of glycolysis activation. Taken together, the above results have identified
that the enhancement of glucose metabolism is an early event induced by BCRABL through its kinase activity.
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Figure 4.

Activation of BCR-ABL enhances glucose metabolism in TonB210
cells. The medium lactate product released from differentially
treated TonB210 cells was measured.

Lactate amount was

normalized by cell numbers. Doxycycline 0.8 µg/ml was used to
induce BCR-ABL expression for 48 hours. Imatinib 5µM was used
to inhibit BCR-ABL tyrosine kinase activity.

Active form and total

BCR-ABL were detected by Western blotting using phosphor-BCRABL and c-ABL antibody.
presence of IL3.
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Figure 5.

No decrease of oxygen consumption rate in BCR-ABL overexpressing cells. Doxycycline 0.5 µg/ml was used to induce BCRABL expression in TonB210 cells. Oxygen consumption rate was
detected using 8 million cells for each sample.
expressing cells were collected at 12 and 36 hour.
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4.1.3 Glucose Shortage Results in Decreased Mitochondrial ROS Generation in
BCR-ABL Expressing Cells.
The level of cellular ROS and mitochondrial ROS were measured under
normal or glucose shortage conditions by probing with DCF-DA and MitoSox
Red, respectively.

Both cellular and mitochondrial ROS elevations induced by

BCR-ABL were suppressed under the glucose shortage conditions (Figure 6). In
addition, no dramatic cell death was induced by glucose shortage (Figure 7),
which excludes the interruption of cell survival as the cause of ROS decrease.
To further prove this point, mitochondrial ROS generation was detected under
the glucose shortage conditions in human cultured CML cells.

Mitochondrial

ROS level was measured in two BCR-ABL positive CML cell lines K562 and
KBM5 using MitoSox Red probe.

After 20 hour glucose shortage culture,

mitochondrial ROS dramatically dropped in both cell lines (Figure 8). In addition,
the effects of glucose shortage on cell survival were tested in K562 cells. There
was no dramatic cell death caused by 24 hours of glucose shortage (Figure 9,
Upper). Just a slight increase of cell death was induced by 48 hour glucose
shortage (Figure 9, Lower).

Taken together, my results suggested that

mitochondrial ROS are highly rely on the glucose nutrient condition, although
glucose shortage does not promote potent cell death in BCR-ABL expressing
cells.
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Figure 6.

Glucose shortage decreases BCR-ABL induced cellular and
mitochondrial ROS increase in TonB210 cells.

Cellular and

mitochondrial ROS levels were detected by Using flow cytometry
using

DCF-DA

and

MitoSOX

Red

probes,

respectively.

Doxycycline 0.8µg/ml was used to induce BCR-ABL expression for
48 hours.

Cells were cultured with or without glucose supply.

Sample’s medians are labeled.
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Figure 7.

No dramatic cell death induced by 48 hour glucose shortage in
TonB210 cells. DNA content was detected by PI staining assay.
Doxycycline 0.8 µg/ml was used to induce BCR-ABL expression for
48 hours. Cells were cultured with or without glucose supply for 48
hours. Percentages of sub-G1 population (lethal cell) are labeled.
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Figure 8.

Glucose shortage results in mitochondrial ROS decrease in K562
and KBM5 cells. Mitochondrial ROS level was detected by flow
cytometry using MitoSOX Red. Cells were cultured with or without
glucose supply for 20 hours. Sample’s medians are labeled.
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Figure 9.

No dramatic cell death induced by glucose shortage in K562 cells.
Cell death was detected by Annexin-V/PI assay.

Cells were

cultured with or without glucose supply for 24 or 48 hours.
Percentages of survival cells are labeled.
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4.2

BCR-ABL Downstream Survival Factor BCL-XL Plays an Essential

Role in Protecting Mitochondria Under Oxidative Stress.
4.2.1 BCL-XL Protects CML Cells Against Oxidative Stress-Induced Apoptosis.
BCR-ABL inducible TonB210 cell model was used to test whether either
BCL-XL or BCL-2 is the primary survival factor during BCR-ABL induction.
Because TonB210 parental cells were cultured with IL-3, which may promote
BCL-XL expression, experimental samples were incubated with low levels of IL-3
at 0.1ng/ml. More specifically, cells were first incubated with doxycycline in the
media containing 1.0 – 4.0 ng/ml IL-3.
decreased to 0.1ng/ml.

After 48 hours, the IL-3 level was

After another 12 hours, control and experimental

samples were collected. Expression of BCR-ABL, BCL-2 and BCL-XL were then
analyzed by Western blotting.

BCL-XL but not BCL-2 was dramatically up-

regulated by over-expression of BCR-ABL (Figure 10). These results suggested
that BCL-XL is an initial survival factor promoted by BCR-ABL.

This evidence

has also implied that BCL-XL may play an important role in response to BCRABL-promoted cellular metabolic alterations, such as oxidative stress. However,
both BCL-XL and BCL-2 have been reported to be up-regulated in CML cells.
Whether BCL-XL is more essential to protect cells against oxidative stress is still
unclear. To further test this point, two human cultured CML cell lines, which
express different levels of BCL-XL and BCL-2 were used to compare cell
sensitivity to oxidative stress.

CML cell line K562 and KBM5 were both

established from CML blast crisis patient samples. K562 showed a relatively
higher level of BCL-XL but less BCL-2 than KBM5 (Figure 11).
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Figure 10.

Initial up-regulation of BCL-XL by BCR-ABL. Doxycycline 0.8 µg/ml
was used to induce BCR-ABL expression in TonB210 for 48 hours,
followed by a decrease of IL-3 to 0.1 ng/ml in the medium. Then
medium IL3 level was decreased to 0.1 ng/ml. Cell samples were
collected after additional 12 hour Doxycycline incubation.

Cell

lysates were analyzed by Western blotting for protein expression
using c-ABL BCL-XL and BCL-2 antibodies. Actin was used as a
loading control.
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Figure 11.

Different expression levels of BCL-XL, BCL-2 and antioxidants in
K562 and KBM5 cells.

Cell lysates was analyzed by Western

blotting for protein expression using BCL-XL, BCL-2, MCL-1, GPX1 and Catalase antibodies. Actin was used as a loading control.
The cell lysate of AML cell line HL60 was used as a control to
indicate the relative level of BCL-XL, BCL-2, MCL-1 and GPX-1 in
CML cells.
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It is worthy of noting that antioxidant enzymes GPX1 and catalase, which
play major roles in scavenging intracellular ROS products under normal
physiological conditions, are both expressed at lower levels in K562 than KBM5
cells (Figure 11). These results suggested a lower antioxidant capacity in K562.
To test CML cell sensitivity to oxidative stress, K562 and KBM5 cells were
incubated with H2O2, a general oxidative stress inducing agent, at 50 µM for 18
hours. In addition, cells were also treated with 0.5 µM Imatinib for 60 hours to
test the cell sensitivity of BCR-ABL inhibition. Interestingly, H2O2 caused more
cell death in KBM5 cells, however, Imatinib promoted more cell killing effects in
K562 cells (Figure 12). These results indicated that K562 cells are less sensitive
to oxidative stress than KBM5 cells.

Therefore, BCL-XL which is highly

expressed in K562 cells seems to play a more dominant role in protecting CML
cells against oxidative stress than BCL-2.

However, these results were

generated from the comparison between different cell lines and it is possible that
other genetic differences between K562 and KBM5 cells may be also involved.
To further clarify the role of BCL-XL in protecting cells against oxidative stress,
either BCL-XL expression plasmid or Bcl-XL shRNA plasmid was transfected into
cultured human CML cell lines. In this experimental system, I can exclude the
impacts derived from genetic background of different cell lines.
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Figure 12.

K562 is less sensitive to oxidative stress induced apoptosis than
KBM5 cells. Cells were treated with 50 µM H2O2 or 0.5 µM Imatinib
for 18 or 60 hours respectively. Flow cytometry was used to detect
cell death by Annexin-V/PI.
labeled.
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KBM5 cells were transfected with a neo’-containing HA tagged human
BCL-XL plasmid. The successfully transfected cells were enriched by selector
G418 for one month. The selected cell pool was named as KBM5-BCLXL-HA.
The over-expressed BCL-XL product was identified by Western blotting using
BCL-XL and HA antibodies (Figure 13). KBM5 and KBM5-BCLXL-HA cells were
incubated with 50 µM H2O2 or 2 µM Imatinib for 24 or 48 hours respectively. Cell
death was detected by flow cytometry using Annexin-V-FITC and PI.

The

increased cell survival of KBM5-BCLXL-HA under treatment of either H2O2 or
Imatinib was observed (Figure 14). In addition, I used the same approach to
generate BCL-XL over-expressing cells from K562, named as K562-BCLXL-HA
(Figure 15). K562 and K562-BCLXL-HA cells were treated with 50 µM H2O2 or 2
µM Imatinib for 60 hours. Consistent with the results from KBM5 pair cells, the
increased cell survival of K562-BCLXL-HA under treatment of either H2O2 or
Imatinib was also observed (Figure 16).

These results have shown that over-

expression of BCL-XL in CML cells reduces cell sensitivity to both oxidative
stress and Imatinib. Besides these gain of function tests, I further investigated
BCL-XL loss of function effects in K562 cells. K562 cells were transfected with
RFP linked tet-on inducible Bcl-XL shRNA plasmids. The successful transfected
cells were enriched by selector 4 µg/ml puromycin for one month, named as
K562-BCLXL-KD. After 4 day doxycycline induced shRNA expression, the BCLXL level was decreased about 70% (Figure 17). After induction of BCL-XL knock
down, cells were treated with 50 µM H2O2 for 24 hours. Apoptotic cells were
further detected by flow cytometry using Annexin-V-FITC staining assay. The
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pre-apoptotic and apoptotic cells indicated as annexin positive were dramatically
increased in BCL-XL knocked down cells (Figure 18).

Taken together, these

results have demonstrated that BCL-XL play an important role in protecting CML
cells against oxidative stress.
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Figure 13.

Over-expression of BCL-XL in KBM5 cells.

KBM5 cells were

transfected with HA tagged human BCL-XL plasmids.

The

successful transfected cells were enriched by selector G418 for one
month, named as KBM5-BCLXL-HA. The over-expressed product
was identified by BCL-XL and HA antibodies. The HA tagged BCLXL protein showed a higher molecular weight than the endogenous
one. Actin was used as a loading control.
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Figure 14.

Over-expression of BCL-XL enhances cell survival under oxidative
stress and Imatinib treatment in KBM5 cells. KBM5 and KBM5BCLXL-HA cells were treated with 50 µM H2O2 or 2 µM Imatinib for
24 or 48 hours respectively. Cell viability was detected by AnnexinV/PI assay. Percentages of survival cells are labeled.
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Figure 15.

Over-expression of BCL-XL in K562 cells.

K562 cells were

transfected with HA tagged human BCL-XL plasmids.

The

successfully transfected cells were enriched by selector G418 for
one month, named as K562-BCLXL-HA.

The over-expressed

product was identified by BCL-XL and HA antibodies. Actin was
used as a loading control.
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Figure 16.

Over-expression of BCL-XL enhances cell survival under oxidative
stress and Imatinib treatment in K562 cells.

K562 and K562-

BCLXL-HA cells were treated with 50 µM H2O2 or 2 µM Imatinib for
60 hours.

Cell viability was detected by Annexin-V/PI assay.

Percentages of survival cells are labeled.
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Figure 17.

Knock-down of BCL-XL in K562 cells. K562 cells were transfected
with RFP linked tet-on inducible Bcl-XL shRNA plasmids.

The

successful transfected cells were enriched by selector puromycin
for one month, named as K562-BCLXL-KD. The BCL-XL level was
identified by Western blotting using BCL-XL antibody after 4 day
shRNA induction by doxycycline treatment. Actin was used as a
loading control.
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Figure 18.

Down-regulation of BCL-XL enhances oxidative stress induced
apoptosis in K562 cells.

Doxycycline-Induced and non-induced

BCLXL knock down cells were treated with 50 µM H2O2 for 24
hours. Cell apoptosis was detected by Annexin-V (including preapoptosis and apoptosis cells).

Viable cells are annexin negative,

while apoptotic cells are annexin positive. Percentages of gated
cells are labeled.
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4.2.2 BCL-XL but not BCL-2 Prevents Oxidative Stress-Induced Mitochondrial
Membrane Potential Collapse.
The above results have shown that KBM5 expresses relatively higher
BCL-2, but is more sensitive to oxidative stress-induced apoptosis than K562
(Figure 11, 12).

This observation implies that BCL-XL and BCL-2 may be

functionally distinct in response to the increased mitochondrial ROS in CML cells.
Both BCL-XL and BCL-2 have mitochondrial localization. Previous studies have
shown that both BCL-2 and BCL-XL play important roles in the development of
CML. BCL-2 especially causes Imatinib resistance in some BCR-ABL positive
and BCR-ABL-independent CML cells. Therefore, identification of the differential
role of BCL-XL and BCL-2 in response to mitochondrial oxidative stress can help
us further understand the biological mechanism of CML progression, and even
provide the rationale for the design of novel therapeutic approaches. To achieve
these goals, I generated BCL-2 over-expressing cells by transfecting a GFPfused BCL-2 plasmid into K562 which has low endogenous BCL-2 background.
The successfully transfected cells were enriched by G418 selection, and the cell
pool was named as K562-BCL2-GFP. Expression of GFP-BCL-2 fusion protein
was identified by Western blotting using BCL-2 antibody (Figure 19A).
Mitochondria localization of GFP-BCL-2 fusion protein was identified by confocal
microscope using MitoTracker Red to indicate mitochondria. The co-localization
of GFP and MitoTracker Red showed that a large amount of the over-expressed
BCL-2 products were successfully localized to mitochondria (Figure 19B).
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Figure 19.

Over-expression of BCL-2 in K562 cells.
transfected with GFP-fused BCL-2 plasmids.

K562 cells were
The successfully

transfected cells were enriched by selector G418 for one month,
named as K562-BCL2-GFP. (A) The over-expressed product was
identified by BCL-2 antibodies.

The GFP fusion BCL-2 protein

showed at a higher molecular weight than the endogenous one.
Both K562 and K562-BCLXL-HA were used as negative controls.
Actin was used as a loading control.

(B) The mitochondria

localization of this GFP-BCL-2 fusion protein was identified by
confocal microscope (40X) using MitoTracker Red and DAPI
indicating mitochondria and nuclei respectively. Cells that showed
the co-localization of GFP-BCL-2 (green) and mitochondria (red)
are indicated by arrows.
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I further detected cell viability of BCL-XL or BCL-2 over-expressing K562
cells under treatment of H2O2 or Imatinib by PI staining assay. The sub-G1
population of each sample indicates the dead cells with decreased DNA
contents. After 48 hour treatment, both K562-BCLXL-HA and K562-BCL2-GFP
cells showed protection effects against H2O2 and Imatinib (Figure 20 Upper).
After 72 hour treatment, however, only over-expression of BCLXL protected cells
against oxidative stress. In contrast, both over-expression of BCLXL and BCL2
still effectively prevented Imatinib-induced cell death following a 72 hour
treatment (Figure 20 Lower).

These results have suggested that BCL-2 is

equally effective as BCL-XL in protecting cells against inhibitors of BCR-ABL, but
is less efficient in preventing oxidative stress induced apoptosis than BCL-XL.
This observation is consistent with the results I found in the comparison between
KBM5 and K562 (Figure 12). It is suggested that BCL-XL is more efficient to
protect cells against oxidative stress than BCL-2, and BCL-2 is more likely to
delay oxidative stress induced apoptosis in CML cells. To further address the
differential role of BCL-XL and BCL2, I tested the effects of the elevated oxidative
stress on mitochondrial membrane potential in CML cells.

Following the

treatment of 100 µM H2O2, cell viability and mitochondrial membrane potential of
CML cells were detected by Annexin-V/PI and Rhodamine 123 staining assays
respectively. The total cell count including pre-apoptotic and apoptotic cells was
matched with the total cell count of cells with collapsed mitochondrial membrane
potential (Figure 21).

These data indicated that the collapse of mitochondrial

membrane potential is an early event and contributes to cell apoptosis. I further
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compared oxidative stress induced mitochondrial membrane potential changes
between the BCL-XL and BCL-2 differentially expressing cells. K562 was found
less sensitive to 50 µM H2O2 induced mitochondrial membrane potential collapse
than KBM5 (Figure 22). Consistently, BCL-XL but not BCL-2 over-expressing
cells prevented 50 µM H2O2 induced mitochondrial membrane potential collapses
(Figure 23). Taken together, these results have suggested that BCL-XL and
BCL-2 differentially protect cells against oxidative stress, and BCL-XL is more
efficient in maintaining mitochondrial membrane potential and preventing
apoptosis than BCL-2.

77

Figure 20.

BCL-XL is more efficient in protecting cells against oxidative stress
than BCL-2.

K562, K562-BCLXL-HA and K562-BCL2-GFP cells

were treated with 50 µM H2O2 or 2 µM Imatinib. Cell death and cell
cycle were detected by PI DNA content staining assay following 48
hour treatment (Upper) and 72 hour treatment (Lower). The DNA
content low sub-G1 population represents the dead cells.
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Figure 21.

Moderate oxidative stress promotes mitochondrial membrane
potential (MMP) collapse and contributes to cell apoptosis in CML
cells.

K562 cells were treated with 100 µM H2O2 for 24 hours.

MMP and cell death were detected by Rhodamine 123 and
Annexin-V/PI

respectively.

Decreased

Rhodamine

123

fluorescence indicates the MMP collapsed cells. Percentages of
MMP collapsed and maintained cells are labeled. Percentages of
survival (Lower left), pre-apoptosis (Lower right) and apoptosis
(Upper right) are labeled.
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Figure 22.

K562 is less sensitive to oxidative stress-induced mitochondrial
membrane potential (MMP) collapse than KBM5. K562 and KBM5
cells were treated with 50 µM H2O2 at different time points. MMP
was detected by Rhodamine 123.

Decreased Rhodamine 123

fluorescence indicates the MMP collapsed cells. Percentages of
MMP collapsed cells are labeled.
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Figure 23.

Over-expression of BCL-XL but not BCL-2 prevents oxidative stress
induced mitochondrial membrane potential (MMP) collapse. K562,
K562-BCLXL-HA and K562-BCL2-GFP cells were treated with 50
µM H2O2 for 72 hours. MMP was detected by Rhodamine 123.
Decreased Rhodamine 123 fluorescence indicates the MMP
collapsed cells. Sample contains MMP collapsed cells shown in
the divided peak pattern. The peaks are indicated by arrows.
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4.2.3 BCL-XL but not BCL-2 Maintains Cell Mitochondrial Integrity Under
Oxidative Stress.
The

above

results

suggested

mitochondria against oxidative stress.

that

BCL-XL

specifically

protects

However, whether BCL-XL protects

mitochondria by limiting mitochondrial ROS generation or enhancing cell
tolerance of oxidative stress was not answered. Therefore, I further tested the
intracellular and mitochondria ROS generation caused by the treatment of H2O2.
No dramatic difference was observed between BCL-XL over-expressing cells and
the parental cells (Figure 24).

This result indicated that H2O2 is effective in

promoting mitochondrial oxidative stress in both cells and BCL-XL mediated
protection effects on mitochondria is not through limiting mitochondrial ROS
generation.

Furthermore, I tested the mitochondrial integrity under oxidative

stress. Mitochondrial respiratory complexes are the major functional components
and are localized on the mitochondria membrane space.

The stability of these

proteins can indicate the function and integrity of mitochondrial organelles. I
treated K562, k562-BCLXL-HA and K562-BCL2-GFP with H2O2 for 48 and 96
hours.

Cell lysates were collected and blotted with different mitochondrial

complex marker subunits. A dramatic loss of mitochondrial complex II 30KD
subunit was observed in K562 and K562-BCL2-GFP but not in K562-BCLXL-HA
(Figure 25).

Along with this change, endogenous BCL-XL was also found

decreased in K562 and K562-BCL2-GFP but not in K562-BCLXL-HA (Figure 25).
These results indicated that BCL-XL plays an important role to maintain the
stability of mitochondria and mitochondrial membrane bound complexes under
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oxidative stress.

Additionally, I also blotted these samples with PARP and

Capase3 antibodies to evaluate the apoptosis activation.

Interestingly, the

cleavage of Caspase3 and PARP was only observed in K562 (Figure 25).
However, the decrease of PARP was found in K562-BCL2-GFP, but no cleaved
Caspase3 was detected (Figure 25). More important, there was no oxidative
stress-induced cleavage of either PARP or Capase3 in K562-BCLXL-HA (Figure
25). These results have demonstrated that BCL-XL functions in both protecting
mitochondria and preventing apoptotic activation against oxidative stress. On the
other hand, BCL-2 can not protect mitochondria against oxidative stress but still
plays a role in inhibiting apoptotic activation.
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Figure 24.

Over-expression of BCL-XL can not prevent oxidative stress
induced mitochondrial ROS increase. K562 and K562-BCLXL-HA
cells were treated with 50 µM H2O2 for 2 hours.

Cellular and

mitochondrial ROS levels were detected by DCF-DA and MitoSOX
Red respectively. Medians of different samples are labeled.
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Figure 25.

BCL-XL maintains mitochondria integrity and inhibits apoptosis
activation under oxidative stress.

K562, K562-BCLXL-HA and

K562-BCL2-GFP cells were treated with 50 µM H2O2 for 48 or 96
hours.

The cell lysates were blotted with antibodies of

mitochondrial respiratory complex specific subunits, BCL-2, BCLXL, HA, PARP and Caspase3. Actin was used as a loading control.
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4.3

Redox Modulation Reagent PEITC Induces Potent Cell Killing Effects

in Imatinib-Resistant CML cells.
The figures and texts in this section have been cited and revised from
‘Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural
compound PEITC through redox-mediated mechanism. Leukemia. 2008
Jun;22(6):1191-9.’
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4.3.1 PEITC Increases Cellular ROS and Depletes Cellular GSH in ImatinibResistant Cells.
‘Imatinib mesylate (Gleevec) is a BCR-ABL tyrosine kinase inhibitor that is
very effective in the clinical treatment of CML.

However, a set of BCR-ABL

mutants, especially the T315I mutation, leads to alteration in the three-dimension
structure of the enzyme active site and exhibits continuously kinase activity and
resistance to Imatinib.
treatment of CML.

Such Bcr-Abl mutations impose new challenges in

Based on the previous observations that the BCR-ABL

oncogenic signal can promote ROS generation and induce cellular redox
imbalance, I postulated that such oxidative stress might serve as a biochemical
basis for preferentially triggering ROS-mediated damage to CML cells by further
oxidative stress with exogenous ROS-generating agents. My study was design to
test this hypothesis using β-phenylethyl isothiocyanates (PEITC) as an agent to
modulate cellular redox status in CML cells. PEITC has previously been shown
to effectively disable the cellular glutathione system by inducing depletion of
cellular glutathione and inhibition of glutathione peroxidase activity, and cause
the massive ROS accumulation in cancer cells.

92

123

It should be noted that the

plasma PEITC concentrations in the µM range were clinically achievable through
oral administration. 124’114
To evaluate the biological basis for my above strategy design, the
correlation between BCR-ABL induced cellular ROS generation and intracellular
GSH status was tested.

BCR-ABL inducible cell line TonB210 was used to

detect the level of cellular ROS and GSH along with the over-expression of BCRABL. The parellel increase of intracellular GSH and cellular ROS upon BCR-ABL
induction (Figure 26) was observed. This data suggested that the cellular GSH is
likely served as cellular defense component responsive to BCR-ABL-promoted
ROS elevation. Based on this suggestion, the biological effects of PEITC on
Imatinib-resistant CML cells were further investigated. ‘KBM5-T315I cells were
significantly less sensitive to Imatinib (IC50 = 5.4 ± 0.07 µM) than the parental
KBM5 cells (IC50 = 0.28 ± 0.05 µM, p<0.0001), and approximate 30% of KBM5T325I cells remained viable after treatment with even 10 µM of Imatinib (Figure
27).

In agreement with my previous prediction, the incubation of KBM5 and

KBM5-T315I cells with PEITC led to a significant increase in cellular ROS.
KBM5 and KBM5-T315I cells treated with 10 µM of PEITC for 90 minutes
showed the dramatic increase of cellular ROS by 129% and 282%, respectively
(Figure 28). Additionally, I also confirmed the GSH depletion caused by PEITC
in both KBM5 and KBM5-T315I cells. Incubation of cells with 10 µM PEITC
caused about 30-40% depletion of glutathione at 5 hour, and a complete
depletion at 10 hour in both KBM5 and KBM5-T315I cells (Figure 29). Because
N-acetylcysteine (NAC) is a precursor for glutathione synthesis, pre-incubation of
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cells with NAC would protect cellular GSH pool. I found that pre-incubation with
2 mM NAC largely restored cellular glutathione, even with 10 hour PEITC
treatment (Figure 29).

This result has suggested that NAC can be used as

negative regulator of PEITC in my experimental system.’ 114
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Figure 26.

Over-expression of BCR-ABL elevates cellular GSH along with
increased ROS. Doxycycline 0.5 µg/ml was used to induce BCRABL expression in TonB210 cells. Flow cytometry was used to
detect cellular GSH and ROS level by CMFDA and DCF-DA,
respectively.
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Figure 27.

KBM5-T315I cells are resistant to Imatinib-induced cell growth
inhibition. KBM5 and KBM5-T315I cells are cultured with Imatinib
at 0, 1, 3, 6, 10 and 30 µM. Cell growth was analyzed by MTT
assay. (Cited from Zhang H. et al. 2008 Leukemia) 114
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Figure 28.

PEITC promotes ROS generation in both KBM5 and KBM5-T315I
cells. KBM5 and KBM5-T315I cells are cultured with PEITC (10
µM, 1.5 hours).

Cellular ROS contents were measured by flow

cytometric analysis after the cells were stained with CM-H2DCF-DA
fluorescence dye. (Cited from Zhang H. et al. 2008 Leukemia) 114
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Figure 29.

PEITC depletes cellular GSH in both KBM5 and KBM5-T315I cells.
KBM5 (A) and KBM5-T315I (B) cells were incubated with 10 µM
PEITC in the presence or absence of 2 mM NAC for 5 or 10 hours
as indicated.

Total cellular glutathione contents were then

measured by using DTNB-enzyme cycling glutathione assay kit.
(**): The GSH is undetectable in the sample. (Cited from Zhang H.
et al. 2008 Leukemia) 114
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4.3.2 PEITC Effectively Promotes Apoptosis in Cells Expressing T315I-BCRABL Mutant Protein.
‘Based on the hypothesis that the increase of ROS generation in CML
under the stimulation of BCR-ABL oncogenic signal might render these cells
highly dependent on glutathione to maintain redox balance, depletion of
glutathione by PEITC would cause severe ROS accumulation and trigger cell
death. Since T315I mutation retains the constitutive tyrosine kinase activity, CML
cells with this mutation should, like their parental, exhibit increased ROS stress
and sensitive to PEITC.
In contrast to the results from Imatinib treatment (Figure 27), both KBM5
and KBM5-T315I cells were equally sensitive to PEITC, with the IC50 values of
3.1 ± 0.08 for KBM5 cells and 2.8 ± 0.42 for KBM5-T315I cells (Figure 30A).
Especially, at 10 µM, PEITC caused complete inhibition of cell growth in both
KBM5 and KBM5-T315I cells (Figure 30A). The potent activity of PEITC in killing
both KBM5 and KBM5-T315I cells was further demonstrated by annexin-V/PI
assay. Exposure of CML cells to 10 µM PEITC for 24 hours resulted in 66% and
63% acute cell death in KBM5 and KBM5-T315I cells, respectively (Figure 30B).
This result was further confirmed in a pair of murine cell lines derived from BaF3
by stably transfecting with either the wild-type or T315I mutant Bcr-Abl.

As

expected, PEITC was also effective in inducing apoptosis in both murine cell
lines, whereas Imatinib caused cell death only in BaF3-BCR-ABL cells but not in
BaF3-BCR-ABL-T315I cells (Figure 31). I further tested the ability of PEITC in
killing primary CML cells isolated from patients who were clinically resistant to
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Imatinib treatment. The primary CML cells from two Imatinib-resistant blast crisis
patients also exhibited resistance to Imatinib in vitro. The CML cells from a
patient with T315I mutation were particularly resistant to Imatinib, with the IC50
value more than 50 µM (Figure 32A).

In contrast, the CML cells from both

patients were equally sensitive to PEITC in vitro, with the IC50 values of 8.3 and
10.5 µM, respectively (Figure 32B).

Consistently, flow cytometry analysis

revealed that incubation with 10 µM PEITC for 24 hours caused more than 50%
cell death in the primary CML cells of both patient samples (Figure 32C). MTT
assay of a total of 6 CML patient samples showed that the IC50 values of PEITC
were 13.6 ± 4.04 µM (Table 1). In contrast to the potent cytotoxicity in primary
CML cells, PEITC exhibited relatively low cytotoxic effects on normal
lymphocytes isolated from healthy donors. Figure 33 shows the dose-response
curves of two representative normal lymphocytes samples. The mean IC50 value
of PEITC in normal lymphocytes was 31.5 ± 5.3 µM, which was significantly
higher than that of the primary CML cells (P=0.002). In summary, the above
results has identified that PEITC is effective in killing CML cells harboring T315I
mutation, which confers resistance to tyrosine kinase inhibitor Imatinib. ‘ 114
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Figure 30.

Both KBM5 and KBM5-T315I cells are sensitive to PEITC-induced
growth inhibition and cell death. (A) KBM5 and KBM5-T315I cells
are cultured with PEITC at 0, 1, 3, 6, 10 and 30 µM. Cell growth
was analyzed by MTT assay. (B) Time-dependent induction of cell
death by PEITC in KBM5 and KBM5-T315I cells. Cell death was
detected by annexin-V/PI assay. The number shown below each
panel indicates the percentage of annexin-V and PI doublenegative cells (viable). (Cited from Zhang H. et al. 2008 Leukemia)
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Figure 31.

PEITC induces cell death in BCR-ABL-T315I transformed cells.
BaF3-BCR-ABL and BaF3-BCR-ABL-T315I cells were incubated
with 10 µM PEITC or 2 µM Imatinib for 24 h, and cell death was
measured by the annexin-V/PI assay. The number shown below
each panel indicates the percentage of the annexin-V and PI
double-negative cells (viable). (Cited from Zhang H. et al. 2008
Leukemia) 114
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Figure 32.

PEITC induces growth inhibition and cell death in Imatinib-resistant
CML patient samples.

(A, B) Representative dose-dependent

cytotoxic effect of Imatinib (A) and PEITC (B) in primary CML cells
with or without T315I mutation.

Cells were incubated with the

indicated concentrations of Imatinib or PEITC for 72 hours, and cell
viability was measured by MTT assay. (C) Induction of cell death
by PEITC (10 µM, 24 hours) in primary blast crisis CML cells with or
without T315I mutation. Cell viability was measured by annexinV/PI assay. The number shown below each panel indicates the
percentage of viable cells.
Leukemia) 114
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(Cited from Zhang H. et al. 2008
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Table 1.

IC50 values of PEITC in primary Imatinib-resistant CML cells. The
primary Imatinib-resistant CML cells were isolated from 6 patients
clinically refractory to Imatinib.

Cells were incubated with the

gradient concentrations of Imatinib for 72 hours, and cell viability
and the IC50 values were measured by MTT assay. (Cited from
Zhang H. et al. 2008 Leukemia) 114
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Sample#

CML stage

IC50 ±SD (µM)

1

Blast crisis

8.3 ± 0.8

2

Blast crisis (T315I)

10.5 ± 0.8

3

Accelerated phase

10.9 ± 1.5

4

Accelerated phase

13.2 ± 0.9

5

Accelerated phase

16.1 ± 1.6

6

Accelerated phase

16.6 ± 1.0

Mean±SD

12.6 ± 3.3
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Figure 33.

Normal donors are less sensitive to PEITC-induced cell growth
inhibition. Cells isolated from normal donors were incubated with
the indicated concentrations of PEITC for 72 hours, and cell viability
was measured by MTT assay.
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4.3.3 PEITC Induces BCR-ABL Cleavage and Degradation.
‘Furthermore, since many proteins, include BCR-ABL, contain redoxsensitive cysteine residuals which can be oxidized by ROS and affect protein
structure and stability, I speculated that induction of severe ROS stress in CML
cells might potentially alter the redox status of BCR-ABL and render it vulnerable
to degradation.
Based on the observations that PEITC caused a substantial increase in
cellular ROS, I tested the possibility that PEITC might alter the protein stability of
wild-type and T315I mutant BCR-ABL. Exposure of KBM5 and KBM5-T315 cells
to 10 µM PEITC caused a and time-dependent decrease of the 210 kD BCR-ABL
protein. The decrease of total BCR-ABL proteins occurred as early as 4 hour of
PEITC incubation, with a concurrent appearance of a 52-kD cleavage product
(Figure 34). The ability of PEITC to induce degradation of wild-type and mutant
BCR-ABL proteins was further confirmed in BaF3-BCR-ABL and BaF3-BCRABL-T315I cells, which express the single isoform of BCR-ABL (Figure 35).
Since caspase-3 activation and the cleavage of poly (ADP-ribose) polymerase
(PARP) are hallmarks of apoptosis, I analyzed the cleavage of caspase-3
(activation) and PARP at various time points after cells were treated with PEITC,
and evaluated the temporal relationship between the protein cleavage, BCR-ABL
degradation, and apoptosis activation. It appeared that caspase-3 activation and
PARP cleavage occurred before BCR-ABL degradation, and that the cleavage of
all these three proteins proceeded well before cell death (Figure 34, Figure
30B).’114
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Figure 34.

PEITC induces cleavage of BCR-ABL and BCR-ABL-T315I mutant
correlated with caspase-3 activation.

PEITC induced time-

dependent cleavage of BCR-ABL, caspase-3 and PARP in KBM5
and KBM5-T315I cells. Cells were incubated with 10 µM PEITC for
the indicated times, and protein cleavage was detected by
immunoblotting using the respective specific antibodies.
from Zhang H. et al. 2008 Leukemia) 114
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Figure 35.

PEITC induces decreases of BCR-ABL and BCR-ABL-T315I
mutant in BCR-ABL over-expressing cells.

PEITC treatment

induces a time-dependent decrease of BCR-ABL levels in BaF3BCR-ABL and BaF3-BCR-ABL-T315I cells. Cells were incubated
with 10 µM PEITC for the indicated times, and protein cleavage
was detected by immunoblotting using the respective specific
antibodies. (Cited from Zhang H. et al. 2008 Leukemia) 114
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‘To further test if caspases or proteasome might be involved in mediating
PEITC-induced BCR-ABL degradation, I used chemical inhibitors of caspases or
proteasome to evaluate the role of these enzymes. Pre-treatment of cells with 20
µM Z-VAD-FMK, a common inhibitor of multi caspases, effectively prevented the
cleavage of the wild-type and T315I-mutant BCR-ABL protein, as evidenced by
the preservation of the full-length (210 KD) BCR-ABL and suppression of the
generation of the 52kD BCR-ABL (Figure 36, lanes 4-6).

Interestingly, the

proteasome inhibitor MG132 (5 µM) did not prevent the cleavage of BCR-ABL to
52 KD fragment (Figure 36, lanes 7-9), but only delay the loss of full length
protein at the early time point (Figure 36, lane 8). This held true for both the wildtype and T315I-mutant BCR-ABL. Thus, it appeared that the PEITC-induced
cleavage of BCR-ABL into 52-kD fragment was largely mediated by a caspase,
whereas proteasome might only play a complementary role to accelerate further
degradation. This is in agreement with the previous observations that caspase-3
is a redox-sensitive enzyme
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and that inhibition of proteasome by MG132 may

affect caspase activity in a ROS-dependent manner.

Furthermore, I

demonstrated that Z-VAD-FMK was able to significantly reduce PEITC-induced
cell death in both KBM5 and KBM5-T315I cells, whereas MG132 exhibited little
effect in preventing apoptosis (Figure 37), consistent with the important role of
caspase in mediating degradation of BCR-ABL.

Because Z-VAD-FMK is a

broad-spectrum caspase inhibitor, these results did not allow the identification of
the specific caspase responsive for the cleavage of BCR-ABL. I then tested if ZDEVD-FMK, a specific inhibitor of caspase-3, could prevent BCR-ABL cleavage
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and suppress PEITC-induced cell death. I identified that inhibition of caspase-3
by Z-DEVD-FMK exhibited similar preventive effects on BCR-ABL cleavage and
cell death as the pan-caspase inbitor Z-VAD-FMK (Figure 38, Figure 39). This
result suggested that caspase-3 is the key effective protease that mediates
PEITC-induced degradation of BCR-ABL and apoptosis. This is in line with the
previous observations that the normal c-ABL protein is a substrate of capase-3
and that this protein structural feature is preserved in BCR-ABL chimeric protein.
126-129

Taken together, the above results have suggested that the cleavage of

BCR-ABL might not be the primary event that triggered apoptosis. The previous
identified biochemical changes induced by PEITC, such as glutathione depletion
and ROS accumulation, might be the initial factors to cause cell death in CML
cells. More likely, the decrease of BCR-ABL may just accelerate the progress of
capase-3 mediated apoptosis.’ 114
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Figure 36.

Pan caspase inhibitor prevents PEITC-induced cleavage of BCRABL and BCR-ABL-T315I mutant. KBM5 and KBM5-T315I cells
were treated with PEITC with or without a 1-hour pre-treatment with
20 µM Z-VAD-FMK or MG132. BCR-ABL and BCR-ABL cleavage
was detected by immunoblotting. (Cited from Zhang H. et al. 2008
Leukemia) 114
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Figure 37.

Pan caspase inhibitor prevents PEITC-induced cell death in KBM5
and KBM5-T315I cells. KBM5 and KBM5-T315I cells were treated
with PEITC with or without a 1-hour pre-treatment with 20 µM ZVAD-FMK or MG132. Cell viability was measured by annexin-V/PI
assay. The number shown below each panel indicates the annexinV/PI double-negative cells (viable).
2008 Leukemia) 114
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(Cited from Zhang H. et al.
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Figure 38.

Caspase-3 inhibitor prevents PEITC-induced cleavage of BCR-ABL
and BCR-ABL-T315I mutant. KBM5 and KBM5-T315I cells were
treated with PEITC with or without a 1-hour pre-treatment with 20
µM Z-DEVD-FMK.

BCR-ABL and BCR-ABL cleavage was

detected by immunoblotting.
Leukemia) 114
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(Cited from Zhang H. et al. 2008
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Figure 39.

Caspase-3 inhibitor prevents PEITC-induced cell death in KBM5
and KBM5-T315I cells. KBM5 and KBM5-T315I cells were treated
with PEITC with or without a 1-hour pre-treatment with 20 µM ZDEVD-FMK. Cell viability was measured by annexin-V/PI assay.
The number shown below each panel indicates the annexin-V/PI
double-negative cells (viable).
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4.3.4 Elevated Intrinsic Oxidative Stress Mediates PEITC Cellular Effects.
‘To further demonstrate the essential role of oxidative stress in mediating
PEITC induced cell killing effects in CML cells, I used the antioxidant N-acetylcysteine (NAC) and the H2O2 scavengering enzyme catalase to evaluate the
importance of ROS induced by PEITC.

Pre-incubation of cells with 2 mM

antioxidant NAC almost completely suppressed PEITC-induced ROS increase
(Figure 40A) and prevented cell death (Figure 41) in both KBM5 and KBM5T315I cells. These results have suggested that intracellular ROS elevation might
play an important role in mediating the cytotoxic effect of PEITC. Interestingly,
pre-incubation with catalase at 500 units/ml only partially reduced PEITC-induced
ROS increase (Figure 40B), and did not decrease cytotoxicity (Figure 41).
However, the same concentrations of catalase fully prevented cell death induced
by exogenous H2O2 (Figure 41). Because catalase is only functional in extracellular space, the difference I observed above has suggested that the oxidative
stress induced by PEITC is intrinsic, and this intrinsic stress is important to
promote apoptosis. Consistent with this observation, Western blotting analysis
showed that only NAC prevented the PEITC-induced cleavage of BCR-ABL
(Figure 42, Lane 7-9), whereas catalase did not suppress BCR-ABL degradation
(Figure 42, Lane 15-16). These data also suggested that the intracellular redox
buffer components are important for the stability of BCR-ABL, and the elevated
intrinsic oxidative stress might render it vulnerable to degradation.’ 114
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Figure 40.

NAC prevents PEITC-elevated ROS in KBM5 and KBM5-T315I
cells. Changes in ROS content in KBM5 and KBM5-T315I cells
were measured following treatment with10 µM PEITC for 1.5 hours
with and without a 1-hour pre-treatment with 2 mM NAC or 500
units/ml bovine catalase. Intracellular ROS was detected by CMH2DCF-DA fluorescent dye (control, purple; NAC or catalase,
green; PEITC, pink; PEITC + NAC or catalase, blue). (Cited from
Zhang H. et al. 2008 Leukemia) 114
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Figure 41.

NAC prevents PEITC-induced cell death in KBM5 and KBM5-T315I
cells. Cells were treated with 10 µM PEITC for 40 hours with or
without a 1-hour pre-treatment with 2 mM NAC or 500 units/ml
bovine catalase. For comparison, cells were also treated with 100
µM H2O2 in the presence or absence of 500 units/ml catalase as a
positive control for catalase activity. Cell death was determined by
the annexin-V/PI assay.

The number shown below each panel

indicates the annexin-V and PI double-negative cells (viable).
(Cited from Zhang H. et al. 2008 Leukemia) 114
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Figure 42.

NAC prevents PEITC-induced BCR-ABL cleavage in KBM5 and
KBM5-T315I cells.

Time-dependent cleavage of BCR-ABL

following PEITC treatment with or without a 1-hour pre-treatment
with 2 mM NAC or 500 units/ml catalase.

BCR-ABL protein

expression was detected by immunoblotting. (Cited from Zhang H.
et al. 2008 Leukemia) 114
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4.4

Imatinib and ABT737 Enhances the Sensitivity of CML Blast Crisis

Cells to Oxidative Stress-Induced Apoptosis.
4.4.1 Establishing K562-Mix, an in vitro Model with Heterogenic Expression of
BCL-XL and BCL-2.
the single target drug BCR-ABL inhibitor Imatinib has high selectivity and
low side effects. However, CML cells may exhibit uneven response to Imatinib
resulted from their phenotypic heterogeneity. Especially, in some cases, Imatinib
is effective to inhibit BCR-ABL activity in CML cells, but the alternative survival
pathway promotes CML cell survival.
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To solve this problem, the therapeutic

strategy to limit the survival role of alternative pathway should be developed. It
would be useful to establish an experimental model with the heterogenic
expressions of cell survival factors. In this model, the phenotypic genotype of the
drug sensitive or resistant population could be identified.

Therefore, the

experimental model, K562-Mix was established to detect the drug sensitivity of
CML cells with different BCL-XL and BCL2 expressions. Besides K562-BCLXLKD (Figure 17) and K562-BCL2-GFP (Figure 19), another cell pool K562-BCL2GFP-BCLXL-KD was generated by over-expression of BCL-2 and downregulation of BCL-XL using GFP fused BCL-2 plasmid and RFP linked tet-on
inducible Bcl-XL shRNA plasmid. The BCL-XL and BCL-2 expression levels of
the different cell pools were detected by Western blotting (Figure 43). K562-Mix
was generated as the mixture of K562, K562-BCLXL-KD, K562-BCL2-GFP and
K562-BCL2-GFP-BCLXL-KD cells.

137

Figure 43.

Establishment of K562-Mix. K562 cells were transfected with GFPfused BCL-2 plasmids.

The successful transfected cells were

enriched by selector G418 for one month, named as K562-BCL2GFP.

K562 cells and K562-BCL2-GFP were further transfected

with RFP-linked tet-on inducible Bcl-XL shRNA plasmids.

The

successful transfected cells were enriched by selector puromycin
for one month, named as K562-BCLXL-KD and K562-BCL2-GFPBCLXL-KD, respectively.

Expression of GFP-fused BCL-2 was

identified by BCL-2 antibodies.

The BCL-XL level after 7 day

shRNA induction was identified by BCL-XL antibody. Actin was
used as a loading control. K562-Mix is the mixture of four cell pools
including K562 parental, K562-BCLXL-KD, K562-BCL2-GFP and
K562-BCL2-GFP-BCLXL-KD.
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The different fluorescence patterns of K562-Mix cells were used to
represent the different BCL-XL and BCL-2 expressions (Table 2).

The

percentage change of the different fluorescence pattern in viable K562-Mix cells
indicates the survival rate of K562-Mix cells with different BCL-XL and BCL-2
expressions. An increased percentage of a cell pool indicates a higher survival
rate or the relative growth advantage of this cell pool in K562-Mix. In contrast, a
decreased percentage indicates a lower survival rate or the relative growth
disadvantage.
In the K562-Mix experimental model, a non-staining method was used to
demonstrate cell viability. Because the dying or dead CML cells often show
smaller cell size due to shrinkage, FSC high was used as the parameter to gate
the survived cell population by flow cytometry. The correlation between FSC
high and cell survival was tested in K562 parental cells by incubation of Imatinib
or H2O2. The FSC high cells showed both Annexin-V and PI negative (viable
cells) in majority (Figure 44). Based on this test, the FSC high cells of K562-Mix
were gated after incubation of Imatinib or H2O2 (Figure 45).

The change of

percentage was evaluated by the fold numbers calculated based on the data
from 24 hour cultured original seed sample (Figure 46, Table 3). K562-BCLXLKD cells, expressing low BCL-XL and low BCL-2 and shown as only RFP positive
in the upper left of each panel, were dramatically suppressed by either Imatinib
or H2O2. This data suggested that CML cells with both low BCL-XL and BCL-2
expressions are hyposensitive to both Imatinib and oxidative stress-induced cell
death.

K562-BCL2-GFP cells, expressing high BCL-XL and high BCL-2 and
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shown as only GFP positive in the lower right of each panel, are the largest
survived population followed with the incubation of either Imatinib or H2O2.
Because I previously identified that over-expression of BCL-2 did not dramatically
enhance K562 cell survival ratio with the 72 hour treatment of H2O2 (Figure 20),
the increased percentage of K562-BCL2-GFP may be caused by the relative cell
growth advantage under oxidative stress. This data indicated that both BCL-XL
and BCL-2 contributes to form the treatment-resistant sub-population from
heterogeneous CML cells.

K562-BCL2-GFP-BCLXL-KD cells, expressing low

BCL-XL and high BCL-2 and shown as GFP RFP double positive in the upper
right of each panel, have increased percentage followed with the incubation of
Imatinib, but not H2O2. This data suggested that oxidative stress may limit the
development of BCL-2-over-expressed Imatinib-resistant cell population when
BCL-XL is down-regulated. K562 cells, expressing high BCL-XL and low BCL-2
and shown as GFP RFP double negative in the lower left of each panel, are
dramatically suppressed by Imatinib, but not that striking by H2O2.
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Table 2.

Correlation between BCL-XL and BCL-2 expression pattern and the
cellular fluorescence in K562-Mix. K562-Mix is the mixture of four
cell pools, including K562 parental, K562-BCLXL-KD, K562-BCL2GFP and K562-BCL2-GFP-BCLXL-KD. Cell pool name, BCL-XL
level, BCL-2 level and fluorescence status of each cell pool are
indicated.
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Figure 44.

Gating viable and apoptotic cells by FSC in K562. K562 cells were
incubated with PEITC or Imatinib. Cell death of gated FSC High or
FSC Low cells was measured by the annexin-V/PI assay.

The

number shown below each panel indicates the percentage of the
annexin-V and PI double-negative cells (viable).
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Figure 45.

Gating viable cells by FSC in K562-Mix.

K562-Mix cells were

incubated with 2 µM Imatinib or 50 µM H2O2 for 72 hours. FSC High
cell population was gated in each sample. The percentage of gated
cells is labeled.
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Figure 46.

Differential cell survival of the different cell pools with the treatment
of Imatinib or H2O2 in K562-Mix. K562-Mix cells were incubated
with 2 µM Imatinib or 50 µM H2O2 for 72 hours. FSC High cell
population was further analyzed according to the expressions of
GFP and RFP. The position of each cell pool is representing as
follows: K562 (Lower Left, GFP-/RFP-, BCL-XL High/BCL-2 Low),
K562-BCLXL-KD (Upper Left, GFP-/RFP+, BCL-XL Low/BCL-2
Low),

K562-BCL2-GFP

(Lower

Right,

GFP+/RFP-,

BCL-XL

High/BCL-2 High), and K562-BCL2-GFP-BCLXL-KD (Upper Right,
GFP+/RFP+, BCL-XL Low/BCL-2 Low). The percentage of each
cell pool in K562-Mix is labeled. The uneven distribution in the
control sample is due to the different cell growth of each cell pool in
K562-Mix.
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Table 3.

Fold changes of the original seeding population under different
treatments.

From the percentage data in Figure 46, the fold

changes of the different cell population in K562-Mix were calculated
between its statistical percentage results from the original seeds
(Left) and the experimental sample (Right). The number shown in
different color indicates increase (Red), no dramatic change (Blue)
and decrease (Green).
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K562-Mix

Control

Imatinib

H2O2-

K562

1.17 ± 0.06

0.32 ± 0.02

0.79 ± 0.03

K562-BCLXL-KD

1.12 ± 0.04

0.14 ± 0.03

0.55 ± 0.07

K562-BCL2-GFP

0.84 ± 0.02

2.02 ± 0.01

1.43 ± 0.01

K562-BCL2-GFPBCLXL-KD

0.83 ± 0.08

1.43 ± 0.13

0.81 ± 0.05

Red: > 1.25, increase
Blue: 0.75 - 1.25
Green: < 0.75, decrease
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4.4.2

Imatinib and ABT737 Enhances Oxidative Stress-induced Apoptosis in

BCR-ABL Cells.
The results from the above experiments have suggested that CML cells
with both high BCL-XL and high BCL-2 expression may have higher chance to
develop into a drug resistant population, and down-regulation or inhibition of
them would enhance cell drug sensitivity.

Based on these suggestions, I

postulated that Imatinib may enhance the sensitivity of oxidative stress-induced
cell apoptosis in its targeting cells through suppression of BCL-XL. In addition,
BCL-XL and BCL-2 inhibitors would be another approach to enhance CML cell
sensitivity to oxidative stress, especially in the cells with BCR-ABL-independent
over-expression of BCL-2. In this study, ABT737, the Bcl-2 homology domain 3
(BH3) mimetic, was used as the pan-BCL-2/BCL-XL inhibitor. ABT737 is the
predecessor of Navitoclax (ABT263) using as a single agent against
lymphoblastic leukemia in clinic trial. ABT737 mediates the functional inhibition
of BCL-XL and BCL-2 as antagonist with no suppression of their expression.
BCR-ABL transformed cell line 32D-p210, derived from the murine
myeloid cell 32D, was used to investigate the effects of Imatinib or ABT737 on
oxidative stress induced apoptosis. Imatinib was identified to induce a dramatic
decrease of BCL-XL in 32D-p210 cells (Figure 47). Pre-treatment of Imatinib or
ABT737 enhanced H2O2-induced cell death in 32D-p210. The percentage of
viable cell was decreased from 89% to 34% or 65% in the combination of H2O2
and Imatinib or ABT737 (Figure 48).
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Figure 47.

Imatinib induces BCL-XL decrease in BCR-ABL-transformed cells.
32D-p210 cells were incubated with 0.25 µM Imatinib for 12 hours.
The change of BCL-XL was identified by Western blotting using
BCL-XL antibody. Actin was used as a loading control.
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Figure 48.

Imatinib and ABT737 enhance oxidative stress-induced apoptosis
in BCR-ABL-transformed cells. 32D-p210 cells were treated with
50 µM H2O2 for 12 hours following the 12 hour pre-incubation of
0.25 µM Imatinib or 2 µM ABT737. Cell apoptosis was detected by
Annexin-V/PI assay. Percentages of survival cells are labeled.
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Based on the results from 32D-p210 study, the effects of Imatinib and
ABT737 on oxidative stress-induced apoptosis were further tested in K562 cells.
Because K562 cells have relative high BCL-XL expression but low BCL-2
expression. The results from K562 would be more representing the effects of
suppression or inhibition of BCL-XL in CML cells. Consistent with the 32D-p210
results, Imatinb caused a decrease of BCL-XL in K562 (Figure 49).

Pre-

treatment of Imatinib or ABT737 enhanced H2O2 induced cell death in K562. The
percentage of viable cell was decreased from 87% to 25% or 79% to 47% in the
combination of H2O2 and Imatinib or ABT737, respectively (Figure 50, Figure 51).
Since the previous observation showed BCL-XL prevents oxidative stress
induced mitochondrial membrane potential collapse (Figure 23), the change of
mitochondrial membrane potential was further measured in the combination of
H2O2 and Imatinib or ABT737. Pre-treatment of Imatinib or ABT737 sensitized
K562 cells to H2O2 induced mitochondrial membrane potential collapse. The
percentage of cells with collapsed mitochondrial membrane potential was
increased from 5% to 37% or 11% to 33% by the combination of H2O2 and
Imatinib or ABT737, respectively (Figure 52, Figure 53). Because BCL-XL is
heavily localized to mitochondria, the change of mitochondria-bound BCL-XL was
investigated in the isolated mitochondria fragments.

A large decrease of

mitochondria-bound BCL-XL was observed in the cells pre-treated with Imatinib
or ABT737 (Figure 54). This data indicated that Imatinib and ABT737 enhance
oxidative stress-induced cell damage through decrease the amount of
mitochondrial BCL-XL.
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Figure 49.

Imatinib induces BCL-XL decrease in K562 cells. K562 cells were
incubated with 1 µM Imatinib for 12 hours. The change of BCL-XL
was identified by Western blotting using BCL-XL antibody. Actin
was used as a loading control.
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Figure 50.

Imatinib enhances oxidative stress-induced apoptosis in K562 cells.
K562 cells were treated with 50 µM H2O2 for 24 hours following the
12 hour pre-incubation of 1 µM Imatinib. Cell apoptosis was
detected by Annexin-V/PI assay. Percentages of survival cells are
labeled.
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Figure 51.

ABT737 enhances oxidative stress-induced apoptosis in K562
cells.

K562 cells were treated with 50 µM H2O2 for 24 hours

following the 12 hour pre-incubation of 2 µM ABT737. Cell
apoptosis was detected by Annexin-V/PI assay. Percentages of
survival cells are labeled.
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Figure 52.

Imatinib

sensitizes

K562

cells

to

oxidative

mitochondrial membrane potential collapse.

stress-induced

K562 cells were

treated with 50 µM H2O2 for 12 hours following the 12 hour preincubation of 1 µM Imatinib. Changes of Mitochondrial membrane
potential were measured by Rhodamine 123 staining assay.
Percentages of the mitochondrial membrane collapsed cells are
labeled.
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Figure 53.

ABT737

sensitizes

K562

cells

to

oxidative

mitochondrial membrane potential collapse.

stress-induced

K562 cells were

treated with 50 µM H2O2 for 12 hours following the 12 hour preincubation of 2 µM ABT737. Changes of Mitochondrial membrane
potential were measured by Rhodamine 123 staining assay.
Percentages of the mitochondrial membrane collapsed cells are
labeled.
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Figure 54.

Imatinib and ABT737 cause mitochondrial BCL-XL decrease in
K562 cells. K562 cells were treated or non-treated with 50 µM
H2O2 for 6 hours following the 12 hour pre-incubation of 1 µM
Imatinib or 2 µM ABT737. Mitochondria fragments were isolated.
BCL-XL was identified by Western blotting using BCL-XL antibody.
BAX, HSP60 and ATP synthase subunit-α were used as the
internal controls.
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4.4.3 Combination of PEITC with Imatinib or ABT737 Promotes Potent Cell
Killing Effects in CML Cells.
PEITC can induce intrinsic oxidative stress and promote massive cell
death in CML cells; however, the major concern of PEITC is its non-specific
oxidative stress effects on normal cells. A proper drug combination to decrease
the minimum effective dose of

PEITC will limit its side effects and enhance its

therapeutic selectivity. The designs of Imatinib and ABT737 were derived from
the concept of targeted therapy. Imatinib and ABT737 specifically suppress their
cellular targeting molecules and only disrupt their targeting cells. Therefore, the
combination of targeted therapeutic agents with PEITC would only drive the
targeted cells hyposensitive to oxidative stress.

Ideally, the lower minimum

effective dose of PEITC and the higher selectivity could be achieved.
PEITC dramatically promoted ROS generation in CML cell lines K562 and
KBM5 (Figure 55). PEITC was used in this experiment at dose of 5 µM, which
has no growth inhibition effect on normal peripheral blood mononuclear cells
(Figure 33). Pre-treatment of Imatinib sensitized K562 cells to PEITC induced
mitochondrial membrane potential collapse.

The percentage of cells with

collapsed mitochondrial membrane potential was increased from 11% to 35% in
the combination of PEITC and Imatinib (Figure 56). Consistently, pre-treatment
of Imatinib enhanced PEITC induced cell death in K562. The percentage of
viable cell was decreased from 70% to 36% in the combination of PEITC and
Imatinib (Figure 57). These results indicated that combination of Imatinib and
PEITC is very potent to promote cell killing effects in CML cells. In addition, pre-
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treatment ABT737 also enhanced PEITC induced cell death in K562.

The

percentage of viable cell was decreased from 67% to 30% in the combination of
PEITC and ABT737 (Figure 58). Because KBM5 cells showed relatively higher
expression of BCL-2, which may delay cell death (Figure 20), inhibition of BCL-2
and BCL-XL by ABT737 would enhance or accelerate oxidative stress-induced
apoptosis in KBM5. As expected, pre-treatment of ABT737 enhanced PEITCinduced cell death in KBM5.

The percentage of viable cell was decreased from

63% to 42% in the combination of PEITC and ABT737 (Figure 59).
Based on the above results, the combination of redox modulation with
suppression of BCL-2 family survival factor function would be an effective
strategy to eliminate CML cells.

Especially, the combination of PEITC with

Imatinib or ABT737 is worthy of further pre-clinical and clinical investigation.
Additionally, my study also suggested that the targeted therapy agents could be
used as the specific sensitizers to decrease the tolerance of malignant cells to a
certain stress.
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Figure 55.

PEITC promotes cellular ROS generation in CML cells. K562 and
KBM5 cells were treated with 10 µM PEITC for 2 hours. Cellular
ROS contents were measured by flow cytometric using CM-H2DCFDA fluorescence dye. Medians are labeled.
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Figure 56.

Imatinib sensitizes K562 cells to PEITC-induced mitochondrial
membrane potential collapse. K562 cells were treated with 5 µM
PEITC for 12 hours following the 12 hour pre-incubation of 1 µM
Imatinib. Changes of Mitochondrial membrane potential were
measured by Rhodamine 123 staining assay. Percentages of the
mitochondrial membrane collapsed cells are labeled.
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Figure 57.

Imatinib enhances PEITC-induced apoptosis in K562 cells. K562
cells were treated with 5 µM PEITC for 24 hours following the 12
hour pre-incubation of 1 µM Imatinib. Cell apoptosis was detected
by Annexin-V/PI assay. Percentages of survival cells are labeled.
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Figure 58.

ABT737 enhances PEITC-induced apoptosis in K562 cells. K562
cells were treated with 5 µM PEITC for 24 hours following the 12
hour pre-incubation of 2 µM ABT737. Cell apoptosis was detected
by Annexin-V/PI assay. Percentages of survival cells are labeled.
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Figure 59.

ABT737 enhances PEITC-induced apoptosis in KBM5 cells. KBM5
cells were treated with 5 µM PEITC for 24 hours following the 12
hour pre-incubation of 2 µM ABT737. Cell apoptosis was detected
by Annexin-V/PI assay. Percentages of survival cells are labeled.
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5. Discussion
5.1

BCR-ABL-Induced Cellular Oxidative Stress.
An increase of ROS has been observed in human CML primary cells by

comparing with the bone marrow cells isolated from healthy donors.

58,59,61

ROS

is believed to mediate multiple biological alterations involved in CML
development.

63

Consistent with previous studies, I have also identified that

higher ROS levels present in BCR-ABL over-expressing cells.

58-60

Additionally,

my study emphasized the supplement of glucose in cell culture is essential to
mediate BCR-ABL-induced the increase of cellular and mitochondrial ROS.
These results suggested that patient’s glucose nutrition conditions and the blood
glucose levels should be considered for CML disease management, especially
for CML prevention purpose. Since the activation of mitochondria by glucose
metabolism is a process involved multiple enzymes involving in glycolysis,
pyruvate consumption and TCA cycle, the related genetic alterations of these
enzymes may be detectable. I compared the expressions of metabolic enzymes
between K562 and normal bone marrow CD34+ cells, based on the profile from
NCBI GEO database. In GEO profile GDS596, most enzymes of glycolysis and
TCA cycle are more expressed in K562 cells than normal bone marrow CD34+
cells (Figure 60, Figure 61). In addition, pyruvate carboxylase, the enzyme
catalyzing irreversible carboxylation of pyruvate to form the critical TCA cycle
intermediate oxaloacetate, is also more expressed in K562 (Figure 62). This
analysis provided the hint of using metabolic enzymes as the biomarker to
evaluate the development of CML.
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Figure 60.

Expression profiles of glycolytic enzymes in K562 cells. GDS596
data profile was downloaded from Gene Expression Omnibus
(GEO) (NCBI). The expressions of glycolysis pathway enzymes in
K562 cells (GSM18897 and GSM18898) were analyzed. CD34+
bone marrow cells (GSM18885 and GSM18886) were used as
controls. The fold changes of gene expression were listed with
gene name and probe codes. Red indicates increase, and green
indicates decrease.
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Figure 61.

Expression profiles of TCA cycle enzymes in K562 cells. GDS596
data profile was downloaded from Gene Expression Omnibus
(GEO) (NCBI). The expressions of TCA cycle enzymes in K562
cells (GSM18897 and GSM18898) were analyzed. CD34+ bone
marrow cells (GSM18885 and GSM18886) were used as controls.
The fold changes of gene expression were listed with gene name
and probe codes.

Red indicates increase, and green indicates

decrease.
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Figure 62.

Expression profiles of Pyruvate carboxylase (PC), pyruvate
dehydrogenases (PDHA1 and PDHB) and lactate dehydrogenases
(LDHA and LDHB) in K562 cells.

GDS596 data profile was

downloaded from Gene Expression Omnibus (GEO) (NCBI).
Pyruvate carboxylase (PC), pyruvate dehydrogenases (PDHA1 and
PDHB)

and

lactate

dehydrogenases

(LDHA

and

LDHB)

expressions of K562 cells (GSM18897 and GSM18898) were
analyzed. CD34+ bone marrow cells (GSM18885 and GSM18886)
were used as control. The fold changes of gene expression were
listed with gene name and probe codes. Red indicates increase,
and green indicates decrease.
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5.2

Differential Roles of BCL-XL and BCL-2 in Protecting Mitochondria

Under Oxidative Stress.
BCL-XL and BCL-2 play important roles in negatively regulating
mitochondria dependent apoptosis through inhibiting Apaf-1 mediated Caspase-9
activation.

131-133

BCL-2 family survival factors maintain mitochondrial integrity by

preventing cytochrome c release.

134

However, there is no clear evidence to

demonstrate the distinct roles of BCL-XL and BCL-2 in response to different
apoptosis stimuli.

Therefore, one goal of my study was to investigate the

efficiency of BCL-XL and BCL-2 in preventing oxidative stress induced cell
damage in CML. According to my results, BCL-XL actually is more essential
than BCL-2 to protect mitochondria against oxidative stress in CML cells.

It is

worthy of noting that unlike BCL-XL, the higher expression of BCL-2 has been
mainly observed in blast crisis patients but not chronic phase CML patients.
135,136

These studies have suggested that BCL-2 is most likely functional as the

secondary survival factor during the development of malignancy in CML.

In

addition, CML malignancy is driven by the myeloid progenitors. The promotion of
cell proliferation in the early stage progenitors is often linked with ROS increase
and differentiation.

137,138

Intriguingly, one recent study has shown that the

expression of BCL-XL and BCL-2 is completely opposite during the differentiation
of human bone marrow mesenchymal stem cells.

139

In this study, researchers

have identified that the expression of BCL-XL is at the similar level in
undifferentiated and differentiated cells, however, BCL-2 only expresses in
differentiated cells. Additionally, they have demonstrated that BCL-XL but not
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BCL-2 plays the dominant survival role in undifferentiated cells.

So the

differential roles of BCL-XL and BCL-2 in response to oxidative stress in CML
cells may involve a cell stage impact.
Previous studies have shown that BCL-XL and BCL-2 also regulate
cellular redox capacity. BCL-XL regulates mitochondrial membrane potential and
protects oxidative stress-caused GSH pool decrease.

69,70

with antioxidants and regulates cellular GSH distribution.

BCL-2 incorporates
140,141

Surprisingly,

BCL-2 has also been viewed as a pro-oxidant to promote mitochondrial ROS
generation.

142

To address such a controversy, the effects of BCL-XL and BCL-2

on BCR-ABL promoted mitochondrial ROS generation were investigated. The
mitochondrial ROS levels of BCL-XL or BCL-2 over-expressing K562 cells were
detected with or without glucose in culture media.

The 5 hour shortage of

glucose caused a decrease of mitochondrial ROS in both BCL-XL overexpressing cells and parental cells, but not in BCL-2 over-expressing cells
(Figure 63). The similar phenomenon also observed through the comparison
between K562 and KBM5. KBM5 cells, with relatively high BCL-2 expression,
were less sensitive to 5 hour glucose shortage-induced mitochondrial ROS drop
than K562 (Figure 64). These results suggested that BCL-2 seems play a role in
maintaining mitochondrial ROS generation in CML, and implied a disadvantage
of BCL-2 in protecting mitochondria under oxidative stress.
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Figure 63.

BCL-2 over-expressing cells are less sensitive to short term
glucose

shortage-induced

mitochondrial

ROS

decrease.

Mitochondrial ROS levels were detected by MitoSOX Red. K562,
K562-BCLXL-HA and K562-BCL2-GFP cells were cultured in
regular or glucose free media for 5 hours.
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Figure 64.

BCL-2 high cells are less sensitive to short term glucose shortageinduced mitochondrial ROS decrease. Mitochondrial ROS levels
were detected by MitoSOX Red.

K562 and KBM5 cells were

cultured in regular or glucose free media for 5 hours. The medians
are labeled.
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5.3

Role of Intracellular GSH Pool for Survival.
My results indicated that the depletion of cellular glutathione appeared to

be an important biochemical event mediating the cytotoxic effects of PEITC.
GSH is viewed as a critical survival antioxidant. A previous study has identified
that the levels of GSH determine cell sensitivity to apoptosis in leukemia cells. 143
Consistently, a severe depletion of GSH before cell apoptosis was found in my
experiments (Figure 29, Figure 30B). Intriguingly, my colleague has identified
that PEITC results in a rapid depletion of mitochondrial GSH and disruption of
mitochondrial metabolism function before inducing an entire cellular GSH pool
loss in leukemia cells.

144

These results suggested that the non-mitochondria

GSH seemed to function as the barrier to prevent the activation of the
downstream steps in apoptosis. Since caspase-3 activation and PARP cleavage
matched the decrease of total GSH in my experiments (Figure 34, Figure 29), I
did an in vitro test to evaluate the effects of GSH levels on caspase-3 mediated
PARP cleavage. I observed that 3 mM GSH prevented the spontaneous PARP
cleavage in CML cell lysates (Figure 65). I further found that 3 mM GSH also
inhibited caspase-3 mediated PARP cleavage in cell lysates (Figure 66). These
results suggested that GSH may play a role in the direct regulation of apoptotic
activation. The potency of PEITC in inducing cell death may be also due to
enhancing cell apoptotic sensitivity by depleting GSH.
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Figure 65.

GSH prevents spontaneous PARP cleavage in vitro. KBM5 cell
pellets were collected. Cell lysate samples were transferred into
100 µl aliquots. The aliquots were incubated in the presence or
absence of 3 mM GSH at 37 °C for 3, 10 or 60 minutes, and then
collected for Western blotting to detect PARP cleavage. The GSH
incubation-caused precipitated proteins were also collected and
blotted with PARP antibody to exclude the precipitation-caused
decrease of cleaved PARP.
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Figure 66.

GSH prevents caspase-3 induced PARP cleavage in vitro. KBM5
cell pellets were collected. Cell lysate samples were transferred
into 100 µl aliquots. The aliquots were incubated in the presence or
absence of active caspase-3 enzymes or 3 mM GSH at 37 °C for
60 minutes, and then collected for Western blotting to detect PARP
cleavage.
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5.4

Potential Advantage of PEITC in Redox-Directed Therapy in CML.
‘The increase of ROS stress in CML cells expressing either wild-type or

mutant BCR-ABL can be exploited for therapeutic purpose. Recently, the redoxdirected therapeutic strategy has drawn researchers’ attention.
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My present

study has suggested that the severe ROS stress induced by PEITC might alter
the redox state of BCR-ABL proteins, including the T315I mutant, and render it
vulnerable to degradation by caspase-3.

This notion is supported by the

observation that either NAC or specific inhibitor of caspase-3 could significantly
suppress the cleavage of BCR-ABL.

It should be pointed out that the

degradation of BCR-ABL may not be the primary cause of PEITC-induced cell
death, which is likely triggered by direct oxidative damage to mitochondria and
other critical cellular molecules. However, the ability of PEITC to induced rapid
degradation BCR-ABL may effectively abolish the pro-survival signal of this
oncoprotein, thus add to the potency of this compound in killing CML cells.
Furthermore, normal lymphocytes have a lower basal ROS output and possess
intact redox-regulatory machinery, which make them less vulnerable to ROS
stress imposed by PEITC. Based on the promising activity of PEITC against
Imatinib-resistant CML cells, its therapeutic selectivity, and its unique mechanism
of action, I conclude that this compound may be useful to overcome CML
resistance to kinase inhibitors.’114
5.5

Potential Advantage of Imatinib in Redox-Directed Therapy in CML.
One of the major concerns of redox-directed therapeutics is the off-

targeting effects on the normal cells. Therefore, the improvement of the
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therapeutic selectivity would make this strategy more beneficial. Oncoprotein
BCR-ABL, encoded by CML specific Bcr-Abl fusion gene, has been identified in
more than 95% CML cases. 45-47 In the past few years, molecular targeting BCRABL functional inhibitors were derived from the concept of targeted therapy and
developed for the chemotherapy of CML.

90

Imatinib specifically suppresses its

cellular targeting molecules and only disrupts the targeted cells.

The

combination of Imatinb with redox modulation agents would only drive the
Imatinib targeting cells hyposensitive to oxidative stress. Therefore, the lower
minimum effective dose of redox modulation agents and the higher therapeutic
selectivity could be achieved.
5.6

Antioxidant Defects in CML.
My results suggested that anti-apoptotic factors play essential roles in

preventing oxidative stress-induced cell damage in BCR-ABL expressing cells.
However, there are other genes, antioxidant enzymes, constantly scavenging
ROS in normal physiological conditions. Why do CML cells highly rely on the
anti-apoptotic factors? Are the antioxidant enzymes deregulated in CML cells?
These are the questions left for future studies.
One of the major antioxidant enzymes, GPX1, has been reported to
dysfunction or lost in some BCR-ABL positive patients or cultured human CML
cell lines.

92,108

However, no study has yet demonstrated the link between the

regulation of GPX1 and the induction of BCR-ABL. GPX1 is the selenium (Se)dependent antioxidant enzyme, mainly catalyzing the reduction of the cytosolic
H2O2 using GSH as the substrates. The regulation of cellular GPX1 expression
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is through multiple optional signaling pathways and largely remains unknown.
The binding sequences of PU.1 and p53 have been identified in GPX1 promoter
region.

146,147

It is worth noting that p53 has been reported to be mutated or

deleted in many CML cases.
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In addition, a previous study suggested that

FOXO3a also plays an important role in regulating GPX1 gene expression.
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Furthermore, the inhibition of FOXO3a activity has been observed in v-Abl
transformed cells.150 These studies suggest that BCR-ABL might interrupt the
expression of GPX1 through inhibiting its upstream transcription factors. BCRABL-transformed cell 32D-p210 showed increased phosphorylation at FOXO3a
Thr32, which inhibits FOXO3a activation (Figure 67A). In addition, a decreased
gene expression of GPX1 was also observed in 32d-P210 (Figure 67A, B,
P=0.0017). These data implied that over-expression of oncogene BCR-ABL may
cause some crucial antioxidant defects and render the transformed cells more
dependent on anti-apoptotic factors to respond oxidative stress.
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Figure 67.

Over-expression of BCR-ABL results in FOXO3a inhibition and
GPX1 decrease. (A) Phosphorylation of FOXO3a Thr32 and GPX1
were detected in samples from 32D-p210 and 32D parental by
Western blotting. (B) GPX1 mRNA expression was measured by
quantitative real-time PCR as described in previous Materials and
Methods 3.13.
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6. Summary and Conclusion
In conclusion, the present studies have demonstrated that BCR-ABL
promotes cellular and mitochondrial ROS generation, while elevating the cell
survival factors GSH and BCL-XL to prevent oxidative stress-induced apoptosis.
Enhancement of glucose metabolism by BCR-ABL contributes to the increase of
mitochondrial ROS in CML cells. These findings have provided insight into the
persistent oxidative stress observed in CML cells.

In addition, the current

research has identified the distinct roles of BCL-XL and BCL-2 in preventing
excessive ROS induced apoptosis, which are due to their differential function in
protecting mitochondria against oxidative stress.

Based on the biological

mechanism studies, novel therapeutic strategies were investigated.

PEITC

effectively promotes massive cell death in Imatinib-resistant CML cells through
targeting cellular GSH system. The combination of either Imatinib or ABT737
with PEITC diminishes the protecting effects of BCL-2 family survival factors and
promotes excessive intrinsic oxidative stress; thus showing cell killing effects in
CML cells. This therapeutic strategy could ultimately improve the selectivity and
potency of redox-directed therapy in CML and other hematological malignancies
(Figure 68).
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Figure 68.

Model summarizing the biological basis and clinical implications of
BCR-ABL-induced mitochondrial oxidative stress and cell survival.
Tyrosine kinase onco-protein BCR-ABL promotes mitochondrial
ROS increase through the enhancement of glycolysis. BCR-ABL
down-stream survival factor BCL-XL plays an essential role in
preventing oxidative stress-caused mitochondria damage and cell
apoptosis. Redox modulating reagent PEITC induces potent cell
death in CML cells by depleting GSH and promoting intrinsic
oxidative stress.

Combination of PEITC with BCR-ABL inhibitor

Imatinib or BCL-XL/BCL-2 inhibitor ABT737 strengthens redox
modulation-induced cell death in CML. Glut: Glucose transporter;
HK: Hexokinase; LDH: Lactate dehydrogenase; P: phosphorylation;
TCA: TCA cycle; I,II,III and IV: Mitochondrial respiratory chain
complex I to IV; C: Cytochrome c.
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